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Abstract
The literature on neuropsychological functioning in patients with asymptomatic 
HIV disease is widely discrepant with prominent researchers on either side of the 
debate about whether or not early HIV infection is associated with neuropsychological 
deficits. Many theories have been put forth to account for these varied results, 
including inadequate study design, lack of measures sensitive enough to detect 
differences, and pooling of test scores across individuals that do have deficits, but not 
necessarily in the same areas.
The present investigation was designed to examine the role o f anxiety as a 
possible confounding variable that could account for differences across HIV serostatus 
groups. It also investigated the hypothesis that HIV seropositive and HIV seronegative 
patients differ in terms of their appraisals of their performance and that higher levels of 
anxiety are related to lowered estimation of performance.
The HIV seropositive and HIV seronegative groups in this investigation did not 
differ in terms of their neurocognitive functioning. When the groups were further 
divided in terms of their anxiety level, again there were no differences in their 
neurocognitive functioning. The investigation therefore failed to identify anxiety as a 
contributor to neuropsychological dysfunction in HTV seropositive subjects, however, 
given the lack of HIV group differences in neurocognitive functioning, it did not rule 
out a potential role for anxiety either.
vi
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Further, there was no difference between the groups divided based on HTV 
serostatus and anxiety level in terms of their ability to accurately appraise their 
performance. All participants were able to estimate their performances very accurately.
Finally, medication effects were investigated. There were no differences in 
performance on neuropsychological tests found between the HIV seropositive subjects 
who followed a medication regimen and those who did not.
vii
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Introduction
The latest statistics released by the Centers for Disease Control and Prevention 
(1996) show that through December 31, 1996, 581,429 people in the United States had 
been diagnosed with AIDS. Many more persons are living with HIV, but estimates of 
the number are conservatively skewed because many states do not require health 
department notification of positive tests for HTV, and many people with HIV have not 
yet been tested. The largest percentage of AIDS patients remained men who have sex 
with other men (homosexuals and bisexuals) at 50%, although this percentage has 
declined since monitoring of the disease began. These numbers demonstrate that 
although the first cases of HTV transmission were reported in homosexual men, the 
trend in cases of newly reported HTV infections is away from the homosexual 
population, and toward IV drug users and their partners. In fact, among women, 
heterosexual contact and intravenous drug use accounted for 40 and 34 percent, 
respectively. Of all AIDS cases, 573,800 were adults and adolescents, and 7,629 fell 
into the category of pediatric AIDS (under 13 years of age). Caucasians accounted for 
46.2% of all AIDS cases, 34.9% were African-American, 19.0% were Hispanic, 0.8% 
were Asians or Pacific Islanders, and 0.3% were American Indians or Native Alaskans. 
Heyward and Curran (1989) note that the disproportionately large number of cases in 
African- and Hispanic-Americans can be attributed to intravenous (IV) drug use and 
sexual relations with partners who are IV drug users, and the percentage of African- and 
Hispanic-Americans among AIDS cases continues to climb at a faster rate than among 
any other group.
1
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Through mid-1995 AIDS was listed as the cause of death for 357,598 people in 
the United States and many more people worldwide, but research continues into ways 
to halt the spread of the disease, and according to the CDC the death rate from AIDS in 
1996 was down 19% from the previous year, probably due to advances in medical care 
of HIV-seropositive patients (“AIDS Deaths are Down,” 1997). The causative agent of 
AIDS has been established as the Human Immunodeficiency Virus, or HIV, and the 
means of infection by the virus have been well delineated. The virus is passed from one 
host to another in the bodily fluids - through shared blood, sexual intercourse, and from 
mother to child, in utero or through breast feeding (Gallo & Montagnier, 1989). 
According to Gallo and Montagnier (1989), until a cure can be found, the greatest 
chance of curbing the epidemic is through knowledge about HTV and its modes of 
transmission with the expectation that this knowledge will lead to behavioral changes 
away from risky behavior. A look back at the discovery of HIV is appropriate at this 
point in order to chart the progress that has been made in the study of this disease. 
History of HIV
According to all published reports, the first cases of AIDS in the United States 
were in young homosexual men, and it soon became apparent from their symptoms that 
they had suffered a loss of T-cells (immune system cells). As in the diseases caused by 
Human T-cell Lymphotropic Viruses - 1 and - n, two retroviruses, the immune system 
was compromised, and like these two viruses, the AIDS pathogen had been shown to be 
transmitted through blood and sexual intercourse. Because o f these commonalities,
Gallo and his colleagues (1984) proposed that the agent responsible for AIDS was a
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
retrovirus related to HTLV-I and -II (Gallo & Montagnier, 1989). Retroviruses differ 
from other viruses in that their genetic material is RNA rather than DNA. Whereas in 
all other cells, the flow of genetic information is from DNA to RNA to proteins, the 
flow is reversed in retroviruses. Information coded in viral RNA is converted into DNA 
which is then incorporated into the host cell DNA where it is transcribed to messenger 
RNA, and its proteins are constructed. The retroviruses are able to accomplish this 
reverse transcription with the help of the enzyme reverse transcriptase.
Early in the history of the study of HIV, several teams of researchers claimed its 
discovery, variously labeling it, HTLV-HI, LAV (Lymphadenopathy-associated virus), 
and ARV (AIDS associated retrovirus) (Knapp & VandeCreek, 1990). With the 
development o f more sophisticated techniques for investigation, it was determined that 
all three were the same virus and the name was changed to HIV. HIV is now often 
referred to as HTV-1 to distinguish it from a structural variant HIV-2 which produces 
similar clinical symptoms but is primarily seen in Africa (Knapp & VandeCreek, 1990). 
Because the virus variant most commonly seen within this country is HIV-1, HIV in this 
paper will refer to HTV-1.
Once HIV was isolated, the next step in the process involved determining its life 
cycle and the means by which it causes AIDS.
Pathophysiology of HIV
HIV is a retrovirus, and as most viruses, it cannot replicate on its own. It 
therefore needs the DNA of a host cell to carry out its replication in order to produce 
more viruses. Unlike most viruses, however, because HIV is a retrovirus, it's genetic
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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material is a single strand of RNA rather than DNA. Therefore, in order to insert its 
own genetic material into the host cell's DNA an intermediate step must take place, for 
this conversion of viral RNA to DNA, the virus uses reverse transcriptase.
HIV primarily attacks and destroys T4 immune cells (helper T-lymphocytes) 
which are at the front lines o f the immune system attack on foreign invaders. T4-cells 
are also often referred to as CD4 cells because of the CD4 receptor on the cell's surface. 
According to McDougal, Mawle, and Nicholson (1989), it is most helpful to view the 
infection with HTV in three stages; infection, replication, and consequences for the 
infected cell. The infection phase begins with binding of the virus to the host cell. The 
CD4 receptor has an affinity for a protein on the coat of the virus, gpl20, and binds 
tightly to it. Next, the virus merges with the T-cell and uses reverse transcriptase, to 
transcribe the HIV's RNA into DNA. The DNA is then incorporated into the host cell's 
genetic structure and there it directs the production of new viral RNA and proteins. The 
proteins then combine to form new virus particles (replication phase) (Redfield &
Burke, 1989). The new viruses then bud from the T-cell membrane and infect other 
cells. The death o f the cell is the ultimate consequence of the infection, but the virus 
may, for a time, simply impair the functioning of the cell, or the two could live 
symbiotically until the virus finally kills the cell (McDougal, Mawle, & Nicholson, 
1989).
Originally, it was discovered that HIV could kill the helper T-cells by 
multiplying to great numbers inside them and in that way kill them. This finding led 
many early researchers to propose that viral replication alone was responsible for the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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cell death associated with infection. Since that time, it has been shown that only a small 
fraction of T-cells display the viral replication necessary for the virus to destroy the 
host cells, and this number is not sufficient to account for the extreme 
immunosuppression in AIDS patients. The only way for later researchers to account for 
the large number of cells killed was to postulate other methods of cell destruction. 
Several mechanisms have been proposed and demonstrated in vitro, however it is not 
yet known if these mechanisms actually occur in the body (Redfield & Burke, 1989).
Sodroski, et al. (1986) and Redfield and Burke (1989) have described the 
formation of syncytia as a possible means to explain the mass destruction of T-cells. In 
this formulation, the infected T-cells fuse with uninfected T-cells and form massive 
multinucleated cells that can no longer function properly, and as a result die.
Redfield and Burke (1989) also propose that the infected T-cells that are not producing 
new viral particles may be sought out and killed by the body's natural immune activity. 
Similarly, they describe a way that even uninfected T-cells might be destroyed by the 
patient's own body. In a process that is unique to HIV the gp 120 proteins that are 
normally part of the virus can break off and circulate freely in the body. Because the T- 
cell receptor has such a strong affinity for this protein, it attaches to the free floating 
gpl20. When the immune system recognizes the gp 120 as a foreign agent, it destroys 
the protein and the cell to which it is attached. In this way, healthy T-cells can be 
destroyed by the immune system of which they are a part
Additionally, the CD4 receptor is not limited to the T- cells. It is also found on 
various other cells in the immune system. Hence, the virus can bind to and replicate in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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monocytes, macrophages, and similar cells called tissue-dendritic cells found in the 
skin, mucous membranes, lymph nodes, liver, spleen, and brain (Redfield & Burke, 
1989). Apparently these cells are not destroyed by the HIV, but their functioning is 
disturbed leading to further systemic immunosuppression.
Further complicating this scenario is the fact that it was discovered that the rate 
of cell death differs between non-activated T-cells and T-cells that have been mobilized 
to fight infection (Fouchard, Desportes, Reveil, Leonard, Gallo & Zagury, 1986; 
McDougal, et al., 1985; Redfield & Burke, 1989, Zagury, et al., 1986). Therefore not 
only are patients more susceptible to infectious agents, but when T-cells are activated to 
combat these infections, the activation leads to increased replication of the virus and 
death of the T-cells. Further, when the T-cells are activated to combat the newly 
invading HTV, this stimulates replication of the virus in the same way that another 
infection would, leading to the paradox that the body's very means of fighting the 
disease aids in its proliferation. Regardless of the mechanism of cell death it remains a 
fact that the T-cell count of the HTV infected patient declines throughout his/her life 
and eventually the immune system is so thoroughly compromised that it can no longer 
function.
Physiological Aspects of HIV Disease
According to Rogers and Masur (1989), seroconversion to HTV positive status 
usually occurs between 8 and 12 weeks afier the presumed exposure. Upon 
seroconversion, some patients experience a mononucleosis-like syndrome (Cooper, et 
al., 1985; Redfield & Burke, 1989). The initial symptoms include fever, fatigue,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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swollen glands, sweats, muscle aches, headache, sore throats and often rashes. With 
treatments, however, these symptoms disappear and the patient returns to a healthy 
state. Unfortunately the symptoms disappear, but the virus continues to live in the host. 
The patient can remain in this state for several years, but the next stage of the disease 
will ensue if the patient does not die of other causes. The patient's lymph nodes also 
become chronically enlarged (Redfield & Burke, 1989). According to Redfield and 
Burke (1989) the presence o f the overabundance o f HTV in the lymph nodes 
overstimulates B-cells (another type of immune cell) and keeps them in a chronic state 
of activation, thus causing the lymphadenopathy. Others (Brandon, 1993) have 
suggested that the virus may be "hiding out" in the lymph nodes and replicating at a 
high rate, thus accounting for the lymphadenopathy as well as for the latency period 
after original seroconversion but before symptoms of ADDS appear.
The T-cell count then begins a steady decline and the immune system becomes 
further compromised. Infectious agents enter the body more easily, and they are harder 
to fight. At this point with the T-cell count begins dropping rapidly, opportunistic 
infections, (from normally benign pathogens that may now take advantage of a 
weakened immune system) begin to appear.
The most recent revision of the CDC classification system for HIV disease 
(CDC, 1992) greatly increased the number of AIDS cases being reported over previous 
systems because it takes into account the number o f T-cells remaining in a patient that 
has been diagnosed as HTV positive as well as the number of additional infections that 
the patient suffers. A discussion of this system is pertinent at this time because it helps
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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to illuminate the progression of the disease state. The system consists of three 
categories involving the number of T-lymphocytes the person has, and three clinical 
categories. The three T cell categories are:
Category 1: > or = 500 cell/microliter of blood 
Category 2: 200 - 499 cells/microliter of blood 
Category 3: < 200 cell/microliter of blood 
The three clinical categories include:
Category A: no condition listed in category B or C and one or more of the 
conditions listed in Appendix A.
Category B: Symptomatic conditions present that are not included in category C, 
and the conditions either are attributed to compromised immune functioning, or are of a 
nature to have a clinical course or require management that is complicated by HIV. 
Examples of conditions in category B can be but are not limited to those conditions 
listed in Appendix B.
Category B conditions take precedent over Category A and once a patient has 
entered Category B, he or she cannot be returned to Category A.
Category C: Includes all clinical conditions listed in the AIDS surveillance case 
definition (Appendix C). Additionally, Category C conditions take precedence over all 
others, and once a patient has entered Category C he or she will remain in that category. 
(See Table 1).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Table 1
1993 Revised Classification System for HIV Infection and Expanded AIDS 












1: > or = 500 Al B1 cr
2:200-499 A2 B2 C2*
3: < 200 (AIDS-indicator A3* 
T cell count)
B3* C3*
* = Indicates reportable AIDS cases either based on the number of T-cells per microliter 
of blood, or based on the presence of clinical conditions listed in the AIDS surveillance 
case definition (Appendix A).
Neuropsychological Manifestations of HIV
Early in the history of AIDS research, several groups had already begun to note 
neurological deficits that were affecting the long-term survivors of HIV disease 
(Gopinathan, Laubenstein, Mondale, Krigel, 1983; Herman, 1983; Kermani, Drob, & 
Alpert, 1984). Initially, it was thought to be the result of a subacute encephalopathy due 
to cytomegalovirus, but the finding that HTV could enter the brain led to the theory that 
HIV invades the brain, and disrupts neuropsychological functioning in those who have 
survived the longest (Navia, 1990). In 1986, Navia and his colleagues (Navia, Jordan, & 
Price, 1986b) became the first to define what they termed "AIDS Dementia Complex 
(ADC)." The term AIDS, rather than HTV, was used because at that time, it was not 
widely known that HTV was the pathogen that caused the immune disorder. The 
patients that they described were inpatients who demonstrated disturbance of motor
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
10
performance, behavior, and global cognitive impairment. Hence the term AIDS 
Dementia Complex was coined.
According to Perry (1990), the term is a misnomer because patients have been 
shown to have mental changes without the systemic manifestations of AIDS. Also, 
these early disturbances may not predominantly involve higher cortical functioning (as 
in dementia), and the complex of cognitive, motor, and behavioral impairment may not 
always be present.
In response to criticisms such as Perry's, the American Academy of Neurology 
AIDS Task Force (1991) has proposed a standard nomenclature for the neurologic 
manifestations of HIV-1 infection. The task force has separated the complex into two 
categories. The more severe form, HTV-1 - associated dementia complex or HTV-1 - 
associated myelopathy, includes the complex of disturbed motor performance, 
behavioral changes, and global cognitive impairment sufficient to disrupt social or 
occupational functioning. A less severe form, HIV-1 associated minor cognitive/motor 
disorder, describes the situation in which not all of these deficits are present, or in 
which the disturbance is not great enough to cause impairment in social or occupational 
functioning. By the current CDC classification system, the manifestations of the severe 
form are sufficient for a diagnosis of AIDS, while the manifestations of the less severe 
form are not, although they may be present in persons with AIDS. The task force further 
states that it is not known at this time if the two forms are the same entity, or even if the 
minor form will inevitably progress to the severe form. Despite the recommendations of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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the task force, however, the term AIDS Dementia Complex has continued to be used in 
the literature.
Soon after the first reports of ADC, researchers began to elucidate the exact 
nature of the dysfunction. Investigations were designed to focus on the specifics of the 
disorder such as timing as well as the exact structures and pathways affected by the 
pathogen. It has been estimated that neuropathological abnormalities are present in 
70% to 90% of the brains o f AIDS patients (Ho, Bredesen, Vinters, & Daar, 1989; 
Vinters, Tomiyasu, & Anders, 1989).
Neuroanatomical Changes in HIV Disease
According to Navia (1990), the most frequent structural changes that have been 
noted on CT and MRI consist o f diffuse cerebral atrophy of varying severity, sometimes 
associated with ventricular dilation. He also noted that these changes have been 
detected months before the onset ofovert dementia. Less frequently, either patchy or 
diffuse attenuation of the white matter may be observed on CT scans, although MRI is 
more sensitive in detecting this abnormality. In an earlier paper, he noted that similar 
changes have also been noted in the basal ganglia and the thalamus (Navia, Cho, Petito, 
& Price, 1986a). Wcssdingh ct al. (1993), however, have noted that the structural 
changes seen are relatively mild, and do not provide a satisfying explanation for the 
clinical picture.
Characteristic histological changes that have been noted are most often in 
subcortical structures, primarily in the central white and deep gray matter in the basal 
ganglia and the thalamus, with relative sparing of the cortical structures (Navia et al.,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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1986b). Navia (1990) has reported that positron emission tomography (PET) studies 
show hypermetabolism of radioactive glucose in subcortical structures early, and both 
cortical and subcortical structures late. Additional findings have included focal necrosis 
and vacuolation of the white matter and focal or diffuse demyelination. These changes 
in brain histology can vary extensively between subjects (Navia, 1990). While HIV 
likely enters the brain early in the course of the infection (Chiodi et al., 1987), it is 
unclear when, after the initial insult patients begin to exhibit neurologic impairment. 
Pathological examination of post mortem patients, however, has shown that the severity 
of clinical dementia generally correlates with the extent of brain pathology (Navia et 
al., 1986b). Navia (1990) has also suggested that regional distribution of HIV parallels 
neuropathy findings, with most infected cells in white and deep gray matter structures, 
namely the basal ganglia and thalamus.
Along with the CNS changes of the brain, HTV disease also causes structural 
changes in the spinal cord. As in the brain, the spinal cord suffers similar inflammatory 
changes, with multinucleated cells and vacuolar myelopathy. These changes have been 
noted primarily at the thoracic level (Navia, 1990).
It has already been mentioned that HIV is known to enter the CNS early in the 
course of infection, given that HTV is present in the CSF of individuals in the early 
stages of HTV disease (McArthur et al., 1989; Sonnerborg et al., 1988). It is not known 
if the virus enters by itself, or is transported by infected macrophages, as most data 
suggest that it is the macrophage that is primarily infected (Navia, 1990). There is 
substantial evidence that HIV-1 has a direct causal role in the pathogenesis of ADC and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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ADC is not related to secondary opportunistic infection (Ho et al., 1985; Sidtis et al., 
1993).
Productive infection in the brain and spinal cord occurs in the blood-derived 
macrophages, resident microglia, and multinucleated giant cells (Epstein & 
Gendelman, 1993), and Geleziunas et al. (1992) have noted that the ability of HIV-1 to 
localize in the CNS is probably the consequence of macrophage tropism, rather than an 
affinity for neural tissue. These findings have raised an interesting dilemma in the 
scientific community, and pose a difficult question that many researchers have 
attempted to answer. HIV infects relatively few cells in the CNS, yet dysfunction to be 
accounted for is quite extensive. What is the exact mechanism of tissue destruction that 
causes the neurologic deficits in HTV disease?
Koyanogi et al. (1987) has suggested that neurotropic variants of HIV may be 
partly responsible for the clinical and pathological heterogeneity of ADC. Guilian, 
Vaca, and Noonan (1990) and Lipton (1992) have gone further in suggesting that 
factors other than direct infection may play a role in the development of neural cell 
dysfunction, and others have agreed.
It is generally held that productive HTV infection is restricted to the 
macrophage, and cell loss is relatively absent. Because the degree of neurologic 
impairment is out of proportion to the neuropathy, many researchers today feel that 
brain injury could be due to secondary metabolic processes that result from the HTV 
infection (Hall et al., 1991; McArthur, 1994; Navia, 1990).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Prevailing theories have included destruction of HIV infected neural tissue, and 
other variations of the theory of immune modulated cell destruction. Navia (1990) has 
suggested that neuronal dysfunction could be the result o f macrophage destruction of 
latently infected neural cells, or the release of substances that are toxic to surrounding 
tissues. The majority of researchers have followed the latter course in their 
investigations. Immune system markers such as (32 microglobin (Elovaara et al., 1989), 
quinolinic acid (Heyes et al., 1991), tumor necrosis factor a, and interleukin-6 (Tyor et 
al., 1992) have all been implicated. All of these markers of immune functioning have 
been found in the CSF of HTV seropositive patients. Wiley et al. (1992) have claimed 
that CSF findings correlate well with one another, but not with the extent of HIV in the 
brain, but Heyes et al (1991) have reported that when opportunistic infections are 
controlled for, levels of quinolinic acid (a macrophage product o f tryptophan 
metabolism) parallel neurologic dysfunction. Further, the cytokines IL1, and TNFa 
have been shown to damage neural cells in in vitro cultures (Guilian & Lachman, 1985; 
Selmaj & Raines, 1988). Additionally, (32 microglobins and quinolinic acid levels in the 
CSF fall with Zidovudine (AZT; an antiretroviral medication) therapy (Brew et al.,
1989; Heyes et al., 1991). AZT at least temporarily disrupts HIV replication, and given 
that AZT has been shown to ameliorate ADC (Portegies et al., 1993; Portegies et al., 
1989; Schmitt et al., 1988; Sidtis et al., 1993), this is an important finding suggesting 
that HIV replication in the brain, and therefore production of the immune modulators 
plays an extensive role in neurological dysfunction.
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Another theory of neuronal destruction in HTV disease comes from Epstein and 
Gendelman (1993). They suggest that HIV-1 infected macrophages can initiate 
neurotoxicity, which is then amplified through cell to cell interactions with the 
astrocytes. This theory has not received extensive attention in the literature.
Finally, there is clinical, imaging, and pathologic evidence that dopaminergic 
neural dysfunction may be involved in the progression of ADC (Kieburtz et al., 1991). 
First, a hallmark of ADC is motor impairment Secondly, Kieburtz et al. (1991) found 
that their patients were responsive to L-Dopa, although dopaminergic side effects 
developed rapidly suggesting that dopamine receptors were significantly upregulated. 
Finally, when dopamine blockers were given, ADC patients developed Parkinson-like 
symptoms.
Specific Areas of Dysfunction
While it has been accepted that a majority of AIDS patients will eventually 
experience the neurological symptoms of HTV, the timing of the dysfunction has been 
the subject of considerable debate. Several studies have reported that the decline in 
functioning begins early in the disease, with early loss of cognitive functioning being 
gradual and often overlooked (Navia, 1990), and greater neuropsychological 
dysfunction with increasing severity of HTV disease. For example Grant et al. (1987) 
reported that in their sample, nine percent of seronegative controls, forty-four percent 
of asymptomatic seropositives, fifty-four percent of patients with AIDS related 
complex, and eighty seven percent of AIDS patients experienced some form of 
neuropsychological dysfunction. Others (Janssen et al, 1988; Perry, Belsky-Barr, Barr,
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& Jacobsberg, 1989; Wilkie, Eisdorfer, Morgan, Lowenstein, & Szapocznik, 1990) 
have also argued that asymptomatic HIV positive patients are more likely than 
seronegative controls to demonstrate deficits in performance.
Attention and Concentration. Although Stem, et al. (1991) have argued that 
there are no deficits in the areas of attention and concentration, using the Paced 
Auditory Serial Addition Test, Grant et al. (1987) has shown that there are indeed 
deficits in divided attention. Further, Navia (1990) has stated that patients who have 
retained insight into their illness, have complained of concentration problems stating 
that tasks require much more time, and are laborious. In order to comprehend when 
reading, patients must reread pages several times, and often lose their trains of thought 
during conversations. Finally, he reported that patients become bewildered and 
confused when presented with more than one task simultaneously.
Language. Generally, those researchers that have studied language functioning 
have concluded that patients retain intact language functioning throughout their illness. 
Using a confrontational naming task (the Boston Naming Test) and a word generation 
test (Thurstone Word Fluency), several researchers report that symptomatic HIV 
positive subjects performed as well as seronegative controls (Claypoole et al., 1990; 
Goethe et al., 1989; Janssen et al., 1989; Miller et al., 1990; Olio, Johnson, & Grafman, 
1991; Olio & Pass, 1988; Stem, Sano, Williams, & Gorman, 1989; Tross et al., 1988; 
van Gorp, Miller, Satz, & Visscher, 1989; Wilkie et al., 1990). Contrary to these 
reports, however, Perty et al. (1989) and Stem et al. (1991) report deficits in word
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generation, and Saykin et al. (1988) have found HIV seropositive patients to have 
difficulty on the Boston Naming Test.
Visuospatial Functioning. As with most domains o f functioning, the results are 
split in the area o f visuospatial functioning. On the Block Design subtest, Tross et al. 
(1988) and van Gorp et al. (1989) have found differences between their HTV 
seropositive subjects and controls. Using the Rey-Osterrieth Complex Figure Test, 
however, Poutiainen, Iivanainen, Elovaara, Valle, and Lindevirta (1988) and van Gorp 
et al. (1989) were unable to corroborate these results.
Verbal Memory. In the area of verbal memory functioning, Jansenn et al. (1989) 
and others (Saykin et al., 1988; Wilkie et al., 1992) noted differences between HTV 
seropositive and HTV seronegative subjects on the prose section of the Wechsler 
Memory Scale. Likewise, several investigators have reported deficits in their HIV 
seropositive subjects on the Buschke Selective Reminding Test (BSRT; Stem et al., 
1989; Stem et al., 1991; Wilkie et al., 1990). Unfortunately as in other domains of 
functioning, in the area of verbal memory, a number of studies contradict the findings 
of the previous researchers. Using the Rey Auditory Verbal Learning Test and the 
California Verbal Learning Test, Olio and Pass (1988) and van Gorp et al. (1989) did 
not find differences between HTV seropositive and HTV seronegative subjects.
Likewise, with the BSRT, Claypoole et al. (1990) and Goethe et al. (1989) failed to 
note any differences.
Visual Memory. Similarly, results of testing are mixed in the area of visual 
memory, with several researchers reporting deficits on the Visual Reproduction section
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of the Wechsler Memory Scale (WMS; Olio & Pass, 1988; van Gorp et al., 1989), the 
Rey-Ostemeth Complex Figure Test (van Gorp et al., 1989), and the Digit Symbol 
subtest of the Wechsler Adult Intelligence Scale - Revised (Janssen et al., 1989). For 
every study that reports a difference in performance between HTV seropositive and HTV 
seronegative subjects, it seems that another reports the opposite. For example, using the 
WMS, Grant et al. (1987), Poutiainen et al. (1988), Saykin et al. (1988), and Tross et al. 
(1988) did not find the differences reported by other researchers. Additionally, using 
the Benton Visual Retention Test and the Tactual Performance Test, Saykin et al. 
(1988) failed to find deficits among their HIV seropositive subjects.
Motor Functioning. Using tests of simple psychomotor functioning, several 
researchers (Claypoole et al., 1990; Franzblau et al., 1991; Goethe et al., 1989; Olio et 
al., 1991, Stem et al., 1991) were unable to find the motor deficits that are seen as a 
hallmark of neuropsychological dysfunction in people with HTV associated dementia. 
Others, however, reported differences between HIV seropositive and HTV seronegative 
subjects (Miller et al., 1990; Saykin et al 1988; Tross et al., 1988). On tests of motor 
speed, and information processing, results were equally divergent. According to van 
Gorp et al. (1993), the majority of studies using the Trail Making Test part A failed to 
report any deficits in functioning. By contrast, about half of the studies using Trails B 
have found differences between their HTV seropositive and HTV seronegative subjects. 
Other researchers reported differences in choice reaction time, although not in simple 
reaction time (Perdices & Cooper, 1989; Wilkie et al. 1990; Wilkie et al., 1992). Van 
Gorp et al. (1993) attributed these deficits to cognitive slowing rather than simply to
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motoric factors. They claimed that the "slowing of psychomotor functions where 
thought is wedded to action may be the cardinal feature of HIV encephalopathy" (p. 
171).
Global Cognitive Functioning. In the area of higher cortical functioning, 
Claypoole et al. (1990), Grant et al. (1987), and Stem et al. (1991) all noted deficits on 
tasks of abstract reasoning, whereas the findings of Rubinow, Berettini, Brouwers, and 
Lane (1988) and Saykin et al. (1988) contradicted these results. Poutiainen et al. (1988), 
Rubinow et al. (1988), and van Gorp et al. (1989) reported that intellectual functioning 
was disturbed, and Stem et al (1989), Stem et al. (1991) and van Gorp et al (1989) all 
reported low scores on the Mini Mental State Exam.
While it is generally accepted in the scientific community that people in the late 
stages of HTV disease are susceptible to neurologic complications, not all researchers 
agree that deficits are manifested early in the disease process. For example, several 
researchers (Goethe et al., 1989; McArthur et al., 1989; Miller et al., 1990; Tross et al., 
1988) reported that their investigations revealed no differences between their 
asymptomatic HIV seropositive patients and HTV seronegative controls. In 1988, the 
World Health Organization (cited in van Gorp et al., 1993) stated that there is "no 
evidence that otherwise healthy [HTV seropositive] individuals are more likely to be 
functionally impaired than persons not infected with HTV." Seines et al. (1990) even 
stated that after a follow up of one and one half years there were still no differences 
between HTV seropositive and HIV seronegative subjects. However, in a recent review 
of the literature, White, Heaton, Monsch, and the HTV Neurobehavioral Research
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Center Group (1995) compared the 57 studies of HTV and neuropsychological 
impairment performed to the time of their review and found that according to these 
investigations 35% of HTV seropositive participants evidenced some form of 
neuropsychological deficit as compared to only 12% of HTV seronegative controls in 
these studies.
According to van Gorp, and colleagues (1993), the general consensus among 
HTV researchers is that HTV penetrates the blood-brain barrier shortly after infection, 
and that some individuals will then evidence acute encephalopathic or meningitis-like 
symptoms. Most people, however, show no dysfunction immediately. Although a 
subsample of individuals will later develop ADC, it is not known what determines the 
progression of the dysfunction. Some factors that have been suggested are (1) genetic 
susceptibility of the host, (2) degree of immunosuppression, and (3) whether the variant 
of HTV is neurotropic (Navia, 1990). Satz (cited in van Gorp et al., 1993) also suggested 
that a determining factor of whether deficits will be found is education level. They 
concluded that those studies which found no differences in cognitive functioning used 
subjects with a high level of education and that the differences between asymptomatic 
HIV seropositive patients and seronegative patients were greater among the less 
educated. This contention was supported by investigations of the cognitive reserve 
hypothesis (van Gorp et al 1994; Picano & Klusman, 1993; Salmon, 1994; Stem, 1994). 
The work on cognitive reserve suggests that higher education levels provide a buffer to 
loss of functioning, implying that those patients with higher educational levels can lose 
more of their cognitive capacity before showing deficits (Picano & Klusman, 1993),
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
21
although this may be accounted for by the low test ceilings on many neuropsychological 
measures. Van Gorp et al. (1993) have concluded that although some studies have 
shown impairment it is usually not enough to affect daily functioning, but that infected 
people with less education are at greater risk for such a loss.
It is not disputed that in late stages of HIV disease individuals encounter a 
decline in functioning. The amount of decline is much less clear in the early stages. 
Previously cited studies were primarily of subjects in the end stages. With regard to 
studies involving subjects in the early, asymptomatic phase of their illness, for every 
investigation which finds deficits early on, there is generally another to dispute it.
Seines et al (1990) offered several possible explanations for these discrepant findings. 
First, they noted that in most early studies which reported differences between 
asymptomatic HTV seropositive subjects and HTV seronegative subjects, the samples 
were very small and differences could have been due to chance. In larger studies 
(Goethe et al., 1989; Mauri, Sinforiani, Muratori, Zerboni, & Bono, 1993; McArthur et 
al., 1989; Tross et al., 1988), asymptomatic HTV seropositive subjects did not differ 
significantly from HTV seronegative controls.
Also, in the early studies, education level was poorly controlled (Seines et al., 
1990). In those studies, the HTV seropositive sample tended to be much less educated 
than controls. Heaton, Grant, and Matthews (1986) and Seines et al. (1990) indicated 
that educational levels accounted for significant variance in neuropsychological 
functioning. Picano and Klusman (1993) asserted that brain reserve capacity (BRC) 
may moderate neuropsychological abnormality as HIV disease progresses and may
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partially account for the variability in neuropsychological impairment observed in early 
stages of HTV infection. To get an accurate picture of neuropsychological changes 
throughout the course of HIV disease one must ensure that the sample size is adequate 
and the control group is fairly equally matched to the sample. Finally, it is important to 
use tests that have been shown to be sensitive to the deficits that are typical o f HIV 
seropositive subjects (Newer, Miller, Visscher, & Satz, 1991).
White and her colleagues also outlined other possible explanations for the 
discrepant results including differences in mode of infection of participants and length 
of battery of tests. Studies of intravenous drug users tend to find loss of functions more 
often than investigations which look at only gay men. Battery length, they argued, 
affects results because brain areas affected by the virus vary between individuals, as do 
the difficulties that result. Therefore investigations that compare subjects on only a few 
tests will be less likely to find positive results when trying to uncover deficits because 
many of the subjects are likely to be impaired in one or more areas that may not be 
tested.
Consistent with the report of White and her coIIeagues(1995), Heaton et al. 
(1995), using an 8-hour test battery, compared subjects on the presence or absence of 
impairment (defined as below average functioning in 2 or more domains) rather than 
comparing subjects in specific areas of functioning. Using this more global definition of 
impairment they reported increased rates of impairment at each successive stage of HTV 
infection in their sample of 500 men. They carefully point out, however, that although
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30.5% of their subjects evidenced some form of neuropsychological impairment, 
almost 70% of subjects did not.
Although the exact timing of deficits has been disputed, it is not questioned 
that HIV patients will frequently demonstrate neuropsychological decline as their 
illness progresses. Deficits have been mainly characterized as subcortical in nature with 
dysfunction in the areas of psychomotor functioning, behavior, memory, and cognitive 
performance (Navia et al., 1986b; Price et al., 1988). However, several other areas that 
have been investigated have revealed deficits.
Psychological Components. Relatively few studies in the literature have 
reported changes in psychological status. Increased depression in HIV seropositive 
subjects has been infrequently mentioned (Miller et al., 1990; Poutiainen et al., 1988), 
and the majority of studies reported no differences in mood between HIV seropositive 
and HIV seronegative subjects (Olio & Pass, 1988; Perdices & Cooper, 1989; van Gorp 
et al., 1989). Noting that a typical complaint of HIV seropositive subjects is dysphoria, 
van Gorp suggested that negative findings regarding mood may be due to selection bias 
in many studies. Perhaps people who were depressed did not volunteer to participate. 
Neuropsychological deficits in HTV seropositive subjects, however, cannot be 
accounted for by depressed mood (Grant et al., 1993). Likewise, in the area of anxiety, 
reports have been sparse.
Neuropsychological Consequences of Anxiety
The topic of the effect o f emotional state on test performance has been a subject 
of considerable investigation. In particular, depression is frequently considered to have
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an impact on performance on neuropsychological tests (Gass & Russell, 1986; Heaton 
& Crowley, 1981; Hinkin, et al., 1992; Sackheim, et al., 1992). However, while 
depression has been studied for its potential effects, the literature has largely ignored 
the investigation o f anxiety as an impediment to test performance.
Even undergraduate psychology majors are familiar with the inverted "U" of 
Yerkes and Dodson (1908) in which a graph of test performance follows an inverted 
"U" shape when performance is plotted on the y-axis, and anxiety is plotted on the x- 
axis. At very low levels o f anxiety, performance is poor due to lack of arousal or 
motivation. As anxiety increases, arousal increases, and test performance rises 
proportionately, but past a certain point the anxiety begins to interfere with 
performance by narrowing the focus of attention so that the individual becomes fixated 
on certain stimuli while relatively ignoring the rest. Performance then begins to decline 
with increasing anxiety.
While the Yerkes-Dodson Law has been demonstrated in the laboratory, and 
most people can probably think of examples from their own lives, the study of the 
neuropsychological consequences of anxiety has not progressed far beyond this point. 
Even in the investigations of anxiety, researchers have typically limited themselves to 
the investigation of specific anxiety disorders - anxiety as a trait- rather than to state 
anxiety. Additionally, positive results have typically been reported when using tasks in 
which the anxious subjects' attention was drawn to stimuli relevant to their particular 
anxiety situation.
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Burgess and colleagues (1981) used a dichotic listening shadowing task to 
demonstrate that agoraphobic and social phobic subjects detected a greater number of 
target words (words with phobic relevance) presented to the unattended channel than 
did controls. Foa and McNally (1986) conducted a similar investigation with obsessive- 
compulsive patients and achieved corroborating results. These studies provide evidence 
for an attentional bias in anxiety disorders.
Other researchers have demonstrated that attention can be drawn away from 
ongoing task demands and toward threat cues in the environment (Matthews & 
MacLeod, 1986; MacLeod, Matthews, & Tata, 1986). Reaction times to to-be-detected 
visual probes were longer if the probe coincided with a threat word in a different 
channel (auditory) (Matthews & MacLeod, 1986). In the second study, shorter reaction 
times resulted when subjects were required to report the location of a dot on a screen if 
the dot appeared in the same place where an anxiety related word had been (MacLeod, 
et al., 1986). These, and other investigators have used a modified Stroop task to show 
that color naming latency was longer for threat words than for non-threat words (Geller 
& Shaver, 1976; Matthews & MacLeod, 1985).
However, it seems that while attentional capacity is preferentially drawn to 
threat words over neutral stimuli, researchers have failed to find a threat bias in recall 
and recognition trials. In fact, Mogg, Matthews, and Weinman (1987) found that 
anxious subjects had a higher recognition rate for non-threat words, than for threat 
words.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
26
While it is not questioned that attention is drawn to anxiety provoking stimuli in 
subjects with anxiety disorders, on neuropsychological tests measuring constructs other 
than attention, the anxiety disorders appear to play much less of a role. For example, 
Zalewski, Thompson, and Gottesman (1994) failed to find differences between the 
performance of veterans with Post Traumatic Stress Disorder, Generalized Anxiety 
Disorder, and control veterans on such measures as the Wechsler Adult Intelligence 
Scale - Revised (WAIS-R; Wechsler, 1981) Block Design subtest, the California Verbal 
Learning Test, the Rey-Osterrieth Complex Figure Test, and the Paced Auditory Serial 
Addition Test
Gass, Ansley, and Boyette (1994), however, suggest that state anxiety, rather 
than anxiety disorders may be associated with preoccupations, intrusive thoughts, 
inattention, distractibilty, and anxiety over possible failure. They have demonstrated 
that scores on maze performance and fluency tests (both verbal and non-verbal) are 
mildly associated with a measure of GAD and strongly related to a Minnesota 
Multiphasic Personality Inventory - 2 measure of fearfulness. Likewise, Buckelew and 
Hannay (1986) demonstrated that performance on the Block Design subtest of the 
WAIS-R (Wechsler, 1981) and word fluency tests were sensitive to state anxiety and 
Mueller, (1979, cited in Lezak, 1983) and Pyke and Agnew (1963) found decreased 
abilities on the Digit Span Forward subtest of the WAIS-R in their anxious subjects. 
King and colleagues have also shown that lower scores on the Finger Tapping Test and 
higher times to completion on the form board were related to higher trait anxiety (King, 
Hannay, Masek, & Bums, 1978).
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Impairment in cognitive functioning has been a consistent complaint o f patients 
with anxiety disorders, and is even listed as a criterion for the diagnosis of PTSD 
(American Psychiatric Association (APA), 1994). According to the authors cited above, 
these complaints may be justified.
Attentional Bias in Anxious Persons
The attentional bias produced by anxiety clearly leads to cognitive deficits, but 
it seems equally likely that global deficits may be produced, or at least exaggerated, by 
the anxious person due to hypervigilance to any loss. In the medically compromised 
patient experiencing even slight cognitive decline, anxiety about the losses may lead to 
a misinterpretation of normal test errors as an indication of decline.
Several investigators have noted the negative impact of mood on appraisal of 
cognitive performance in HTV seropositive people. In fact, Perry (1990) reported that 
HIV seropositive people's metacognitions indicate that they feel that their deficits are 
worse than they actually are measured to be. And van Gorp et al. (1991) reported that 
depression is associated with increased cognitive complaints (including forgetting 
appointments and experiencing the tip of the tongue phenomenon), but the number of 
complaints is unrelated to actual deficits. Further, Wilkins et al. (1991) reported that 
although 49% of their subjects reported cognitive complaints, the complaints were 
associated with psychiatric symptoms (including depression and anxiety), but again, not 
with cognitive performance. Van Gorp and colleagues (1993) summarized the relation 
of mood to report of cognitive complaints stating that subjective report o f cognitive 
failures may be more related to an individual's current affective state rather than to
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objective neuropsychological difficulties. However, more recently, Poutiainen and 
Elovaara (1996) have clarified this relation with regard to stage of HIV infection, 
stating "in symptomatic infection 'subjective' complaints may reflect 'objective' 
cognitive deficits, whereas for asymptomatic subjects there may be other reasons for 
such complaints," (p. 224). These studies indicate that anxiety may impact appraisal of 
performance in situations where it does not directly influence performance.
Hypotheses
The current study will attempt to further elucidate the role that anxiety plays in 
the neuropsychological dysfunction in early HIV disease. Given the disparate findings 
in the research literature on HIV seropositive people in the early stages of disease, it is 
possible that with tighter control over previously uncontrolled variables, a clearer 
picture of the neuropsychological sequelae in early HIV disease may emerge; 
suggesting that one or another of these variables may have impacted and confounded 
previously reported results. One variable that has not received extensive attention in the 
HIV literature has been anxiety. Therefore, it is necessary that before the 
neuropsychological deficits in HIV disease be attributed directly to the effects of HIV, 
the possibility that anxiety plays a role in neuropsychological dysfunction in early HIV 
disease must be examined. Hypotheses to be researched in this investigation include: 1) 
HIV seropositive participants will evidence significantly lower performance scores on 
neuropsychological measures said to be sensitive to HIV serostatus than their HIV 
seronegative counterparts, regardless of anxiety level. A main effect is expected for 
HTV serostatus for those neuropsychological measures previously shown to be diturbed
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in people with HIV. 2) Participants high in anxiety will perform more poorly on those 
tests which are sensitive to increased anxiety (a main effect for anxiety level). 3) An 
interaction between HIV serostatus and anxiety level is expected for perfromance 
appraisal scores. The participants high in state anxiety will judge their performances on 
neuropsychological measures to be lower than their actual scores, and that this 
difference will be exaggerated in those individuals with HTV. These findings would 
suggest that neuropsychological deficits which are seen early in HIV disease are not due 
to anxiety but likely are related to the direct effects of HIV on cognitive functioning, 
and that anxious participants would have a tendency to exaggerate their self-report of 
the deficits that they do experience.
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Participants
This investigation received approval from the Louisiana State University 
Medical Center Institutional Review Boards and the Louisiana State University 
Institutional Review Board. Seventy-six participants were recruited from the HTV 
Outpatient (HOP) Clinic at Medical Center of Louisiana at New Orleans (MCLNO) in 
New Orleans, Louisiana. Thirty-eight clinic patients composed the experimental group, 
and the control group was made up of HTV seronegative friends or relatives of HTV 
seropositive individuals seen at this clinic (N = 11) or elsewhere (N = 27). This control 
group was chosen in order to maximize the similarities to the experimental group in 
terms of demographics and anxiety level. No monetary or other compensation was 
offered to the subjects. Potential risks (no serious risks) and benefits (aid in future 
treatment o f HTV patients) of the study were explained, and participants were instructed 
that they could request information on the results of the study, and this information 
would be forwarded to them after completion of the study.
Because this study focused on asymptomatic HTV disease, subjects were 
excluded if their T-cell count was lower than 200 CD4/mm3 of blood, or if they had 
begun to show systemic complications of HIV disease (qualifying for a diagnosis of 
AIDS). All HIV seropositive individuals fell into CDC categories Al, A2, B l, or B2. 
Potential participants were also excluded if they had abused recreational drugs or 
alcohol within the preceding six months, as defined by DSM-IV (APA, 1994) criteria, 
or if they were unable to achieve a sixth grade reading level on the Wide Range
30
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Achievement Test Revision Three (WRAT-3; Wilkinson, 1993). Attempts were made 
to equate all groups on the basis of race, age, sex, education level, and intellectual 
functioning.
Materials
Dependent variables were derived from neuropsychological measures which 
were selected because they have been shown to be sensitive to performance decrements 
among subjects with HIV or anxiety. The neurocognitive areas selected for assessment 
were based on their vulnerability to HTV infection included attention and concentration 
(Paced Auditory Serial Addition Test), learning and memory (Rey Auditory Verbal 
Learning Test), psychomotor speed (Grooved Pegboard), verbal fluency (Controlled 
Oral Word Association Test), and information processing (Trail Making Test Part B). 
Neuropsychological measures sensitive to anxiety included tests that are very difficult 
or elicit the greatest amount o f state anxiety (Buckelew & Hannay, 1986) (e.g., Block 
Design and Digit Span Forward from the Wechsler Adult Intelligence Scale - Revised 
and the Paced Auditory Serial Addition Test). Additionally, a measure of anxiety 
(State-Trait Anxiety Inventory - State form) was utilized to determine group placement, 
and an estimate of intellectual functioning (Shipley Institute of Living Scale) was 
employed as a control variable.
A final dependent variable was the accuracy of the participants appraisal of his 
or her neuropsychological functioning. After administration of each of the 
neuropsychological measures, subjects were asked to estimate their performance on 
that test on a scale o f below average, average, or above average. For each measure, a
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score of -2, -1 ,0 ,1 , or 2 was assigned based on the comparison of the participant's 
appraisal to his or her actual performance level. A score of -2 indicated an appraisal of 
below average for an actual above average performance (the subject appraised his or 
her performance to be 2 steps below his or her actual performance). Subjects who 
appraised their performance one step below their actual performance were given a 
score of -1. Correct appraisals obtained a score of 0, while overestimates of actual 
ability received scores of 1 or 2 depending on the extent of their overestimates.
Negative appraisal scores were summed and the absolute value of this sum constituted a 
dependent variable defined as the extent of the underestimation of his or her 
performance (NEGAPP). Likewise, positive appraisal scores were also be summed to 
yield a dependent variable for the level of overestimation of performance (POSAPP).
The following measures were used in this investigation.
State-Trait Anxiety Inventory. fSTAI: Spielberger, 1983). The STAI assesses 
both level of anxiety symptoms at the time of administration (the state portion, STAI- 
S), as well as the examinee's general level of anxiety (the trait portion, STAI-T). Only 
the STAI-S will be used for this study. The STAI-S has been shown to be internally 
consistent (median alpha coefficient of .92) and concurrently valid (correlation of .77 to 
.84 with other anxiety measures). However, test-retest reliability is low (.16 to .62) 
which reflects fluctuation in anxiety states over time (Spielberger, 1983).
Shiplev Institute of Living Scale. (SILS; Shipley, 1946). The SILS is a paper and 
pencil test consisting of two parts. The first, the verbal section, is a multiple-choice test 
that involves picking from four choices the best synonym for each of the test words.
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The second part is a free response test of abstract reasoning in which the subject must 
complete several incomplete series (for example, the subject may be given the series 
1,2,3,4, and will be asked to fill in the blank). The Shipley total score (Verbal and 
Abstract quotients) provides estimated WAIS (Wechsler, 1955) and WAIS-R 
(Wechsler, 1981) IQ scores and was used as an estimate of intellectual functioning in 
this investigation. Reliability estimates for the Shipley total score range from .78 for 
test-retest reliability to .92 for split-half reliability. Although heavily verbally weighted, 
the Shipley total score has shown a median correlation of .79 with the WAIS (range of 
.73-.90 across 11 studies) and correlations of .74 and .85 with the WAIS-R (Zachary, 
1986).
Rev Auditorv-Verbal Learning Test. CRAVLT: Rey, 1964; Lezak, 1983). The 
RAVLT involves verbal presentation of a list of fifteen nouns (list A) to the examinee 
who is then asked to repeat the list back to the examiner in no particular order (free 
recall portion). After five presentations of the list, a second list of fifteen nouns (list B) 
is presented as an interference trial, followed by a free recall test o f this list. 
Immediately following recall of list B, the original list is requested again to assess 
interference. After twenty minutes, free recall of list A is again tested (delayed recall). 
The RAVLT is well normed for ages thirteen through above seventy and demonstrates a 
test-retest reliability of .55 at one year intervals (Snow, Tierney, Zorzitto, Fisher, & 
Reed, 1988). Alternate forms of the RAVLT correlate in the range of .60 to .77, and in 
factor analytic studies, the RAVLT learning measures correlate .50 to .65 with other 
learning measures (Lezak, 1995). The RAVLT is generally regarded as a measure of
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episodic verbal memory, and is well-normed nationally as well as regionally using 
subjects from Louisiana (Savage & Gouvier, 1992). For the purposes of this study, the 
total recall for trials 1-5 (RAVLTTOT), and the recall on the delay measure 
(RAVLTDLAY) were used as dependent variables.
Trail Making Test. Parts A and B. (TMT; Army Individual Test Battery, 1944). 
The TMT assesses visuospatial search skills, psychomotor speed, and the examinee's 
ability to alternate between cognitive sets within a task (divided attention). The test 
involves connecting a series of circles in numeric order (Part A) and alternating alpha­
numeric order (Part B). In part A the circles are labeled with numbers and must be 
connected in order from lowest to highest number. Part B employs both numbers and 
letters, and the circles are connected in ascending order, alternating between numbers 
and letters. Reliability coefficients for the TMT have ranged from .46 to .98 for part A 
and .44 to .92 for part B (Spreen & Strauss, 1991). Lower reliabilities were from studies 
assessing test-retest reliability in which scores would be expected to improve and 
reliabilities would therefore be lower. Higher reliability ratings were from alternate 
forms. These findings would seem to indicate strong practice effects. The TMT has 
been found to be highly sensitive in detecting brain damage (Dodrill, 1978; O'Donnell, 
1983). The test yielded 2 dependent variables, TMT A, which was the time to 
completion for Part A of the TMT, and TMTB, the time to completion for Part B of the 
TMT.
Block Design. (BD; Wechsler, 1981). This test involves the use of cubes that are 
red on two sides, white on two sides, and half red and half white on two sides. The
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participant is first given four cubes to replicate specific designs. As the test progresses 
in difficulty, the participant is given nine blocks to construct more complex designs. 
Split-half reliability ranges from .83 for 55-64 year old participants to .89 for 
participants aged 25-44. The BD test has also been shown to be sensitive to high levels 
of anxiety (Buckelew & Hannay, 1986). The participant is given 2 chances to correctly 
replicate each of the first 2 designs, and is given 2 points for a correct response on the 
first attempt, and 1 point for a correct response on the second attempt. The participant 
receives at least 4 points for each design correctly replicated after the initial 2 designs. 
Partial credit is not given, however, bonus points are added for speed of performance. 
The dependent variable (BLOCKS) obtained from this measure represented the 
participant’s total score on the measure.
Grooved Pegboard Test. (GPT; Klerve, 1963; Matthews & Klove, 1964). This 
test requires fitting ridged pegs into a board containing a five by five grid of slotted 
holes rotated at various angles. Normally the time to completion for each hand is 
scored. The GPT assesses motor slowing or clumsiness and provides measurements for 
both the dominant and non-dominant hands (Miller et al., 1990). Kelland and 
colleagues (1992) found substantial test-retest reliability (r=.82) with this measure. This 
test also yielded two dependent variables, GPTD, the time required to complete the test 
using the participant’s dominant hand, and GPTN, the time to completion using the 
non-dominant hand.
Digit Span Forward. (DSF; Wechsler, 1981). On this test that is generally 
regarded as a measure sensitive to attention and concentration, the examiner reads
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aloud a series of digits at a rate o f one per second. After the last digit in the series has 
been read, the participant must repeat the digits to the examiner in the exact order in 
which they were presented. The number of digits presented increases as the test 
progresses. The participant is given 2 chances to correctly repeat a sequence at each of 
the specified string lengths. For each string that is correctly repeated, the participant is 
awarded 1 point. The second attempt at each string is administered and scored 
regardless of the participant’s success or failure on the first attempt. The test ends when 
the participant fails to correctly repeat both strings at a given length. Split-half 
reliability coefficients range from .70 for 16-17 year olds to .89 for 25-34 year olds. 
Performance on the DSF has been shown to be sensitive to anxiety (Mueller, 1979 cited 
in Lezak, 1995; Pyke & Agnew, 1963), and is generally not affected in persons with 
HIV disease (Miller et al., 1990). The participant’s score was the number of strings of 
digits correctly repeated. This score constituted the DIGITS variable for this 
investigation.
Controlled Oral Word Association Test. (FAS Test; Benton & Hamsher, 1976; 
Benton et al., 1983). The FAS test is a measure of word fluency or word production.
The examinee is given one minute to generate as many words as possible that begin 
with a specified letter. The letters F, A, and S are most often chosen and will be used 
for this study. The FAS Test has shown high test-retest reliability ranging from .70 at 
one year (Snow et al., 1988) to .88 at 19-42 days (desRosiers & Kavanagh, 1987). The 
FAS Test is well normed and is sensitive in identifying frontal and prefrontal brain 
damage (Spreen & Strauss, 1991). The dependent variable FAS obtained from this
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measure corresponded to the total number of words produced by the participant using 
all three letters.
Paced Auditory Serial Addition Test. (PAS AT; Gronwall, 1977). The PAS AT 
has been used to assess sustained attention and concentration, as well as information 
processing. The test involves auditory presentation to the examinee of a series of digits. 
The participant adds each presented digit to the preceding one, saying the sum aloud. 
The PASAT has shown excellent internal consistency with a split-half reliability 
measure of .96 (Egan, 1988). Spreen and Strauss (1991) have described the PASAT as a 
"very sensitive test of deficit in mildly brain-injured people," (p. 148). Because the test 
is "quite demanding" even for non-injured subjects (Spreen & Strauss, 1991; p. 148), a 
shortened version developed and normed by Rao, Leo, Bemardin, and Unverzagt (1991) 
in which digits are presented at 3 second intervals, then at 2 second intervals was used. 
The score obtained from this measure (PASATTOT) was the sum of the number of 
correct responses given on the two trials.
Procedure
Following the receipt of informed consent, all participants were administered 
the WRAT-3 reading test to determine eligibility for the investigation. The participants 
next completed a short demographic information sheet, and the remaining measures 
were administered to all subjects in the following order:
1) STAI-S
2) SILS
3) RAVLT (free recall portion)
4) TMT Parts A and B
5) Block Design
6) GPT
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The testing order was the same for all subjects because their performances were 
compared against one another, and the study was not intended to examine specific 
deficits within domains of functioning. Therefore, the effects of order of presentation 
were not assessed. The STAI-S was administered first in order to obtain a measurement 
of the subjects’ anxiety levels as testing began. Next, the SILS was administered 
because the score on this test was used as a control variable. The RAVLT was the first 
neuropsychological measure administered because it contains a built in delay that must 
be administered later in the session. The TMT parts A and B , Block Design, GPT, and 
Digit Span followed next in order to fill the time between the RAVLT free recall and 
delayed recall with non-verbal tests that would not interfere with memory of the word 
list for the RAVLT. Next, the RAVLT delayed recall test was administered due to the 
constraint that it must follow the free recall portion by 20 minutes. The FAS test 
followed in order that the PASAT might be administered last due to the high rate of 
failure on this test and the increased anxiety and discomfort it can engender. The order 
of testing was chosen to maximize efficiency, gathering the greatest amount of 
information in the least amount of time while minimizing subject fatigue.
The 1-1.5 hour battery was administered in a single setting. To decrease the 
likelihood of fatigue, a two minute break was offered after the RAVLT delayed recall 
was completed. No breaks were given before that point, as the time between initial 
administration o f the RAVLT and the delayed recall test is fixed at 20 minutes. Testing 
was administered with the examiner sitting across a desk from the subject in a room
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with adequate lighting that was relatively free o f distractions. As stated above, after 
administration of each measure performance appraisals were obtained.
Three examiners were used for this investigation. All examiners were familiar 
with the administration of psychological measures, and used a standardized instruction 
sheet which is reproduced in Appendix D.
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Results
The sample size for the current study totaled 76 participants, 38 o f whom were 
HIV seropositive, and 38 seronegative individuals. Of the participants, 58 (76.3%) were 
white, 17 (22.1%) were African-American, and 1 (1.3%) was Native American. For the 
purposes of the investigation, the latter two groups were combined to yield race 
categories of white, and non-white. Sixty-two (80.5%) participants were male, and 14 
(18.2%) were female. The ages of participants ranged from 19-53 years, with a mean 
age for participants of 34.5 years (SD = 7.4 years). The mean education level was 15.0 
(SD = 2.2 years), with a range of 11 - 20 years. The mean age- and sex- corrected STAI- 
S T-score for all participants was 48.7 (SD = 8.2), indicating that the anxiety level for 
the sample was in the average range when compared to the normative data for the 
measure.
Of the 38 participants with HIV disease, 26 (65.8%) were prescribed (and 
reported taking) one or more anti-retroviral medications (including reverse transcriptase 
inhibitors as well as protease inhibitors). Twelve (34.2%) reported that they either had 
not been prescribed medication, or had chosen not to take those that had been 
prescribed. The mean CD4 count for the HTV seropositive participants was 443.4 
CD4/mm3 (SD = 175 CD4/mm3), and ranged from 210 - 982 CD4/mm3. For a listing of 
demographic information, please see Table 2.
For the first set of analyses, only those subjects whose STAI-S score fell in the 
highest one third of all scores or the lowest one third of all scores were included in the
40
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Table 2
Demographic Information for the Entire Sample and for Each of the HIV Serostatus 
Subgroups.___________________________________________________________
Variable Entire Sample HIV + HIV-
Race
White 58 26 32
Non-white 18 12 6
Sex
Male 62 32 30
Female 14 6 8
Age 34.5 yrs. 34.3 yrs. 34.7 yrs.
Education 15.0 yrs. 14.1 yrs. 15.9 yrs.
STAI-S T-score 48.7 50.3 47.1
CD4 count N/A 443.4CD4/mm3 N/A
Medication status
Yes N/A 26 N/A
No N/A 12 N/A
analyses. Therefore, only participants scoring 51 or higher, or 45 or lower on the STA1- 
S were utilized. When the two groups were further divided according to their HTV 
serostatus, four groups were created. In order to increase the number of participants 
included in the analyses, for those participants with missing PASATTOT scores (N = 
4), the overall sample average PASATTOT score of 83 for the entire sample was 
substituted in place of the missing data. The groups were: low anxious - HIV 
seronegative (N=13), low anxious - HIV seropositive (N=8), high anxious - HIV 
seronegative (N=l 1), and high anxious - HIV seropositive (N=17). Chi-squared tests 
were conducted on these four groups to determine group equality in terms of race and 
sex, and these were found to be non-significant (for X2 values and significance levels 
please refer to Table 3).
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Table 3
X2 Values Comparing HIV Seropositive and HIV Seronegative Participants at High and 
Low Anxiety Levels as Determined Using a Tertile Split of Anxiety Scores.__________
Variable Anxiety Level x- Significance df
RACE Low 0.50 All 1
High 3.02 .082 1
SEX Low 0.03 .854 1
High 0.22 .636 1
To determine group equality for the control variables age, education, and 
Shipley total score, 2 X 2  ANOVA’s were performed using the scores on these tests as 
dependent variables. The groups did not differ significantly in terms of age of 
participants or Shipley total score. However, ANOVA revealed a main effect for HIV in 
terms of years of education with the HTV seronegative subjects being more educated 
(mean = 16.2 years) than those infected with HIV (mean 14.2 years), F(2,48) = 9.46, p < 
.01. Therefore, in subsequent analyses involving these groups, education was entered as 
a covariate to control for any confounding effects.
Multivariate analysis of covariance (MANCOVA) used to examine group 
differences on the measures that assess areas that have been shown to be disturbed in 
patients with HTV revealed no significant two-way interactions, or main effects. While 
examination of univariate tests does not typically follow a non-significant MANCOVA, 
for the purposes of this investigation, the univariate results will be reported to highlight 
areas which may be important to investigate in future endeavors of this nature. 
Examination of the univariate tests, revealed a significant two-way interaction for the 
RAVLT total score (F(l,43) = 2.33, p < .02) in which those participants in the high
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anxious - HIV seropositive group scored significantly more poorly (mean = 41.2, SD = 
7.4) than participants in the low anxious - HIV seropositive group (mean = 51.1, SD = 
4.0). Differing anxiety levels led to differences in scores, but only for those participants 
with HIV. In addition, a main effect was observed for anxiety on the time to complete 
the Trail Making Test part B (F(l,43) = 4.34, p < .05). Group means indicated that 
those participants in the high anxiety groups required longer times to complete the 
measure than patients in the low anxiety group regardless of their HIV serostatus.
A MANCOVA performed on those variables that are frequently disturbed in 
anxious participants again revealed neither a significant two-way interaction, nor a 
significant main effect for either anxiety or HTV serostatus. Examination of the 
univariate tests revealed a significant main effect for anxiety level on the Block Design 
variable (F(l,44) = 4.06, p = .05). Inspection of the group means indicated that those 
participants in the high anxiety groups performed more poorly on the measure than 
those with less anxiety, regardless of their HIV serostatus. For group mean scores on 
each of the measures administered, please see Table 4.
The next set of analyses utilized scores from all participants. The participants 
were again divided into four groups depending on their STAI-S scores, and their HTV 
serostatus, and again the overall sample mean was substituted for all missing 
PASATTOT scores. For the following analyses, however, a median split at the STAI-S 
T-score of 48 divided the participants into low and high anxiety groups. The resulting 
groups were: low anxious - HTV seronegative (N=21), low anxious - HTV seropositive
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Table 4
Mean Test Scores (and Standard Deviations) for each Group (as Created Using a Tertile 
Split o f STAI-S Scores and HTV Serostatus) on Dependent Measures._______________
Measure Lo Anx/HIV-
Group 
Hi Anx/HIV- Lo Anx/HIV+ HiAnx/HTV+
RAVLTTOT 47.2 (9.3) 47.5 (4.6) 51.1 (4.0)* 41.2 (7.4)*
RAVLTDLAY 9.4 (3.3) 9.4 (2.9) 10.0(1.8) 7.2 (3.2)
FAS 42.7 (12.2) 44.5(10.7) 44.8 (10.4) 37.6 (9.9)
GPTD 66.4 (8.5) 64.8 (6.4) 64.0 (12.4) 75.3 (16.0)
GPTN 71.2(12.4) 71.7(11.0) 69.0 (12.4) 81.1 (18.9)
PASATTOT 83.9(19.1) 82.9 (22.4) 83.6(12.5) 75.4 (23.0)
TMTA 22.7 (6.2) 22.5 (7.2) 23.6(6.1) 26.0 (8.9)
TMTB 51.9 (16.4)** 54.4 (20.7) 49.1 (14.0)** 69.9 (20.3)
BLOCKS 34.5(10.1)** 32.7 (8.9) 38.2 (7.4)** 26.4 (9.6)
DIGITS 8.1 (2.7) 9.1 (1.3) 8.4 (2.6) 7.1 (2.3)
Note. Lo Anx/HIV- = Low anxiety - HTV seronegative group; Hi Anx/HTV- = High 
anxiety - HIV seronegative group; Lo Anx/HIV+ = Low anxiety - HIV seropositive 
group; Hi Anx/HIV+ = High anxiety - HTV seropositive group.
* = Indicates the two groups significantly different within the significant interaction.
** = Indicates a main effect with the two groups with highest scores marked with (**).
(N=18), high anxious - HTV seronegative (N=17), and high anxious - HTV seropositive
(N=20).
Chi-squared tests were performed for these groups on the control variables race 
and sex were found to be non-significant, indicating that there were no group 
differences on these variables (see Table 5). The data were then subjected to 2 X 2 
ANOVA's for the variables age, education level, and Shipley total score. As before, 
ANOVA's for age and Shipley total score were not significant, a main effect for HIV 
was again found with regard to education level (F(l,75) = 15.00, p < .001) with the HTV 
seropositive participants being less educated (mean = 14.11 years) than the HIV 
seronegative participants (mean = 15.92 years). As with the previous set of analyses,
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Table 5
X2 Values Comparing HIV Seropositive and HTV Seronegative Participants at High and 
Low Anxiety Levels as Determined Using a Median Split of Anxiety Scores._________
Variable Anxiety Level A2 Significance df
RACE Low 1.04 .308 1
High 1.80 .179 1
SEX Low 0.47 .493 1
High 0.07 .795 1
education was therefore used as a covariate for all analyses using these groups. As 
with the previous set of analyses, the scores on the measures that are often disturbed in 
patients with HTV were subjected to a 2 X 2 MANCOVA. Again, the MANCOVA was 
not significant for the two-way interaction, or for main effects for anxiety or HTV 
serostatus. Examination of the univariate tests revealed no significant group 
differences.
Next, a MANCOVA was performed on the scores for the measures thought to 
be sensitive to differences in anxiety level. This MANCOVA was also non-significant 
for the two-way interaction as well as for main effects for anxiety and HTV serostatus. 
Again, the univariate tests were not significant Group mean scores for each of the 
variables are listed in Table 6.
Finally, the two HIV groups were compared to determine whether they differed 
in terms of their anxiety levels. While the ANOVA on these groups did not indicate a 
significant difference, the difference did approach significance (F(l,75) = 3.00, p < 
.09). For that reason, the variables most often found to be sensitive to HIV serostatus 
were entered into a one-way MANCOVA with education and STAI-S scores entered as
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Table 6
Mean Test Scores (and Standard Deviations) for each Group (as Created Using a 
Median Split of STAI-S Scores and HIV Serostatus) on Dependent Measures.
Measure Lo Anx/HTV-
Group 
Hi Anx/HTV- Lo Anx/HTV+ Hi Anx/HTV+
RAVLTTOT 49.0 (8.8) 49.0 (6.0) 48.6 (8.8) 42.5 (7.5)
RAVLTDLAY 9.8 (2.9) 9.6 (2.9) 9.5 (2.4) 7.6 (3.1)
FAS 44.0 (12.2) 43.2 (9.2) 42.1 (12.0) 38.9(10.9)
GPTD 66.6 (8.4) 65.5 (6.2) 68.5(14.6) 73.5(15.5)
GPTN 71.0(10.6) 73.5(12.4) 74.0(15.8) 80.3 (18.7)
PASATTOT 89.3 (18.9) 82.0 (20.7) 84.0(19.4) 75.8(21.2)
TMTA 22.4 (6.5) 21.9(6.6) 24.4 (6.8) 25.0 (8.7)
TMTB 52.4(14.1) 53.5 (21.3) 58.7(31.6) 66.6 (20.2)
BLOCKS 35.2(10.2) 34.4 (9.3) 35.2(11.2) 26.8 (9.8)
DIGITS 8.7 (2.6) 8.7 (1.6) 8.3 (2.8) 7.4 (2.3)
Note. Lo Anx/HIV- = Low anxiety - HTV seronegative group; Hi Anx/HIV- = High 
anxiety - HIV seronegative group; Lo Anx/HTV+ = Low anxiety - HIV seropositive 
group; Hi Anx/HIV + = High anxiety - HTV seropositive group.
covariates in order to examine differences between the HTV serostatus groups when 
their anxiety level was held constant. This MANCOVA was also found to be non­
significant, as were the univariate follow up tests. For group means on dependent 
variables for each of the HTV groups, please see Table 7.
The second part of the study used the positive and negative appraisal scores 
derived from the participants' assessments of their performances. As described above, 
these scores were computed by asking the participant to rate his or her performance on 
a scale of below average, average, or above average. These judgments were then 
compared to their actual performance in relation to all other participants. From these 
appraisals, two scores were determined, the extent to which the participant 
underestimated his/her performance (NEGAPP) which was the absolute value of the
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Table 7
Mean Test Score (and Standard Deviations) by HIV Serostatus Group on Dependent 
Measures, Controlling for Anxiety Level.______________________ ______ _____—  ----------------
Measure
Group 
HIV seropositive HIV seronegative
RAVLTTOT 45.4 (8.6) 49.0 (7.6)
RAVLTDLAY 8.5 (2.9) 9.7 (2.8)
FAS 40.5(11.4) 43.6(10.8)
GPTD 71.1 (15.1) 66.1 (7.4)
GPTN 77.2(17.4) 72.1 (11.3)
PASATTOT 79.8 (20.4) 86.1 (19.8)
TMTA 24.8 (7.7) 22.2 (6.5)
TMTB 62.8 (26.3) 52.9(17.5)
BLOCKS 30.8(11.2) 34.8 (9.7)
DIGITS 7.8 (2.5) 8.7 (2.2)
sum of his/her under appraisal scores, and the extent to which the participant 
overestimated his/her performance (POSAPP) defined as the sum of his or her over 
appraisal scores.
Two by two ANOVA's were used to determine if the four groups differed in the 
accuracy of their performance appraisals. The first two ANOVA’s were performed on 
the NEGAPP and POSAPP scores of the groups defined by the tertile split (participants 
at the extreme anxiety levels). The second set of ANOVA's was conducted to determine 
if the groups determined by the median split of STAI scores differed significantly on 
NEGAPP or POSAPP scores. None of the ANOVA's were significant, indicating that 
neither a participant's HIV serostatus, nor his/her anxiety level was related to his/her 
ability to accurately judge his/her performance. For NEGAPP and POSAPP scores for 
these groups please see Tables 8 and 9.
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Table 8
Mean appraisals scores per group (as Created Using a Tertile Split of Anxiety Score 
and HTV Serostatus).___________________________________________________
Group
Variable Lo Anx/HIV- Hi Anx/HTV- Lo Anx/HIV+ Hi Anx/HIV+
NEGAPP 2.38 3.00 2.13 1.76
POSAPP 1.54 1.18 1.13 1.94
Note. Lo Anx/HIV- = Low anxiety - HTV seronegative group; Hi Anx/HTV- = High 
anxiety - HIV seronegative group; Lo Anx/HTV+ = Low anxiety - HTV seropositive 
group; Hi Anx/HTV+ = High anxiety - HIV seropositive group.
Table 9
Mean appraisals scores per group (as Created Using a Median Split of Anxiety Score 
and HTV Serostatus).____________________________________________________
Group
Variable Lo Anx/HTV- Hi Anx/HTV- Lo Anx/HTV+ Hi Anx/HIV+
NEGAPP 2.57 3.12 2.22 2.05
POSAPP 1.71 1.06 1.39 1.65
Note. Lo Anx/HIV- = Low anxiety - HTV seronegative group; Hi Anx/HIV- = High 
anxiety - HTV seronegative group; Lo Anx/HTV+ = Low anxiety - HIV seropositive 
group; Hi Anx/HTV+ = High anxiety - HIV seropositive group.
The final analysis was performed to test for medication effects, therefore only 
scores for those participants with HIV were utilized. The HTV seropositive participants 
were divided into two groups based on whether they followed a medication regimen 
(for HTV) or not. In order to increase the number of cases utilized for the analysis, for 
any participant who did not complete the PAS AT (N = 3), the average PAS AT total 
score for HTV seropositive patients (80) was entered as his/her score. A MANOVA 
comparing scores from participants who reported taking HTV medications with those 
who did not on variables that are reportedly disturbed in HTV seropositive patients was 
not significant. Examination of the univariate tests revealed a significant effect for
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medication status for the variable GPTD (F( 1,35) = 5.24, p < .03). Groups means 
indicated that those participants taking medication were slower to complete the 
Grooved Pegboard Test than the patients who were not taking medication. These results 
indicate that for this sample, participants on medication did not perform significantly 
differently from those who were not. Mean scores on the dependent variables for the 
medicated and nonmedicated groups are listed in Table 10.
Table 10
Mean Scores (and Standard Deviations) for Each Dependent Variable for Medicated 




RAVLTTOT 44.1 (9.4) 48.7 (5.4)
RAVLTDLAY 8.1 (3.0) 9.4 (2.6)
FAS 38.6(12.3) 45.0 (7.6)
GPTD 74.6(16.0) 62.8 (8.6)
GPTN 79.7(19.5) 71.4 (9.7)
PASATTOT 77.6 (20.4) 85.4 (18.5)
TMTA 25.3 (8.7) 23.4 (4.7)
TMTB 65.7 (29.7) 55.7(14.3)
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Discussion
Although it would be difficult to find anyone with knowledge in the field to 
dispute the evidence of brain dysfunction in late stage HTV disease, such findings are 
much less clear in patients early in the disease process. The literature on 
neuropsychological functioning in patients with asymptomatic HTV disease is widely 
discrepant, and opinions on the merits of the investigations published, as well as the 
validity of the results are divergent Many prominent researchers have joined the debate 
on both sides of the issue.
A number of investigations have been published in support of each of the 
positions, and several theories have been advanced to explain the varied results. Some 
researchers blame inadequate study design for an inability to find positive results. 
Others have suggested that many of the tests used are not sensitive enough to detect the 
subtle deficiencies of which patients with HIV complain. Finally, some investigators 
have pointed to the notion that areas of deficits differ across individuals, and pooling of 
test scores leads to the lack o f positive findings.
The current study was designed with the intention of ruling out at least one of 
the possible explanations for differences between HTV seropositive and HTV 
seronegative individuals on neuropsychological measures. To date, no studies have 
been published in which possible differing anxiety levels between HTV seropositive and 
HIV seronegative participants have been addressed. Given the literature that test 
performance can be affected by extreme anxiety, it seems possible that this variable 
could influence test performance in patients with HTV. It was the intention of this study
50
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
51
to demonstrate that disturbed performance on neuropsychological tests in HIV 
seropositive participants could not be accounted for by differing anxiety levels, and was 
in fact due to differences in HTV serostatus.
In this investigation, the HIV seropositive and seronegative groups did not differ 
in terms of their performance on the neuropsychological tests administered. 
Additionally, the anxiety level for the two groups was not significantly different. 
However, while they did not differ significantly in terms of their level of anxiety, the 
difference did approach significance. For that reason, their neuropsychological test 
performance was compared while controlling for any differences that may have been 
due to anxiety. In fact, any differences between their performance on the 
neuropsychological measures was even less obvious under these conditions. These 
results would seem to indicate that on the basis of this investigation, anxiety cannot be 
ruled out as a contributor to neuropsychological deficits found in previous 
investigations, but it cannot be identified as a contributor either because the results 
were unchanged under differing anxiety conditions.
To more thoroughly investigate the possible role of anxiety in contributing to 
disturbance in neuropsychological functioning in HIV patients, four groups were 
created based on scores on the STAI-S and the participants' HIV serostatus. It was 
expected that for those tests that in previous studies had evidenced disturbed 
performance in HTV patients, a main effect for HIV serostatus would be observed. 
Additionally, for those tests which have been demonstrated to be sensitive to anxiety 
level, a main effect for level of anxiety was anticipated. Finding these results would
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have indicated that neuropsychological deficits in HIV patients are in fact related to 
differing serostatus regardless of anxiety level. This claim would have been bolstered 
by a main effect for anxiety level on the anxiety sensitive tests which would have 
shown a dissociation between neuropsychological deficits due to HIV and those related 
to anxiety.
The anticipated results, however, were not realized. When the groups were 
defined by a median split of scores on the STAI-S, MANCOVA’s on both the measures 
thought to be sensitive to anxiety level and those thought sensitive to HIV serostatus 
were not significant for the interaction between anxiety level and HIV serostatus, or for 
main effects. Likewise, when the groups were chosen to maximize the difference 
between the anxiety levels (by taking the top and bottom tertiles), the same 
MANCOVA's were again found to be non-significant. The only differences that were 
found were on individual tests in the groups representing the extreme anxiety levels.
The tests on which significant differences were found were the Block Design subtest of 
the WAIS-R and the Trail Making Test Part B (on which the participants high in 
anxiety level performed more poorly), and the total number of words recalled on the 
RA.VLT, which highly anxious participants performed more poorly, but only in the HIV 
seropositive condition. Again, it would seem that from the results obtained in this 
investigation, anxiety cannot be ruled out as a contributor to differences in 
neuropsychological test performance between HIV serostatus groups.
The final hypothesis investigated in this study involved the participants' 
appraisals of their performances. It was thought that those participants who were most
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anxious would be more likely to judge their performance to be lower than the actual 
level, and that this effect would be most pronounced in the HIV seropositive 
participants. The test of this effect was also found to be non-significant. It is unclear if 
the assumption was invalid, or if the method of investigation was faulty. For this study, 
the participants were asked to appraise their performances on the measures given, but, 
as many complained, they had no frame of reference for the measures because they 
were unfamiliar with the tests. Perhaps a better strategy which may have been more 
likely to yield positive results would have been to ask not how they felt about their 
performance on specific tests, but to estimate their abilities in the areas tested.
The question remains why the anticipated main effects for neuropsychological 
performance were not found in this investigation, and what could be changed in future 
research efforts to more accurately examine this population. One problem that likely 
plagued this research as it does many other projects was the influence of selection bias.
It is impossible to determine to what extent the data collected were influenced by 
differences in those people who volunteered to participate, versus those who refused. It 
is very likely that those patients who felt that they had begun to experience cognitive 
losses may have been more reluctant to have this suspicion confirmed, and still others 
may have been less willing to participate due to extreme anxiety invoked by the testing 
situation. In fact, these were the explanations offered by several clinic patients who 
chose not to participate. Ironically, the inclusion of these people would very likely have 
strengthened this investigation.
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Additionally, one might argue that the number of participants in this 
investigation was inadequate to provide significant results. Although this criticism is 
valid, and observed power levels were low, it is important to note that when the F 
values and significance levels for the MANCOVA's were examined, the F values were 
found to be very small, and the probability levels very high. These statistics indicate 
that while the group means were in the predicted directions, the effect size for the 
effects under investigation were sufficiently small that even if enough subjects had 
been recruited to find significance with adequate power, the results would not have 
been any more meaningful in terms of clinical relevance.
One of the requirements for participation in this project was the ability to read 
at a sixth grade level. For that reason, several potential participants were excluded from 
this study, and others refused to participate when they realized that their reading level 
would be assessed. Given the data that differences in neuropsychological test 
performance between HTV seropositive and FIIV seronegative participants are most 
often seen in less educated patients, the exclusion of this group was a shortcoming of 
this investigation. The lack of positive results in this investigation seems to support 
previous findings of a protective effect for higher education levels against cognitive 
loss (Motimer & Graves, 1993; Stem, et al., 1994; Zhang, et al., 1990).
Finally, the majority of the HIV seropositive participants in this investigation 
reported following a regimen o f anti-viral medication. Additionally, because the HOP 
Clinic at Medical Center of Louisiana is an AIDS Clinical Trials Unit, of those on 
medication, all but two had been prescribed protease inhibitors, the newest class of
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anti-retroviral medication. Because of the novelty of these drugs, they have not received 
the investigative attention of older medications. It is known that these medications, 
alone and, more frequently, in combination with reverse transcriptase inhibitors, can 
drop the level of viral RNA copies (viral load) in a patient's blood to undetectable levels 
(Cohen, 1996; Deeks, Smith, Holodniy, & Kahn, 1997). While this has been associated 
with improved physical functioning and longer survival time (Cohen, 1996, Deeks et 
al., 1997), it remains to be seen if this improvement translates into improved cognitive 
functioning as well (although this is likely given the documented improvement in 
cognitive function associated with other anti-retroviral medication (Portegies et al.,
1993; Portegies et al., 1989; Schmitt et al., 1998; Sidtis et al., 1993)). Given that the 
MANOVA comparing those participants taking medication to those participants who 
were not was nonsignificant, it is impossible to point to either a positive or negative 
effect for medication in the HTV seropositive participants. However, when group mean 
scores were considered, the mean scores for all measures for the medication groups 
were lower (though not significantly) than their nonmedicated counterparts. A possible 
explanation for this unexpected finding is that the subjects on medication were the least 
healthy (while viral load estimates were not available, the mean CD4 count of the 
medication groups was lower than that of the nonmedicated group, though not 
significantly) and they therefore did not perform as well as the nonmedicated group. 
Also, given the lack of research on the protease inhibitors, it is possible that they could 
in some way have adversely affected the performance of these participants due to an 
unreported toxic side-effect of the medication.
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Given the criticisms outlined above, several suggestions present themselves as 
ways to improve upon the design of the study. If the study had been funded by an 
outside agency, it would be possible to pay potential subjects, which would likely 
increase participation. The desire for monetary compensation was voiced most often by 
female clinic patients, although it was a consideration for many other potential 
participants regardless of their gender. If the investigator were able to pay the 
participants, the question of selection bias would not have been removed, but it more 
than likely would have been lessened, and a greater number of participants might have 
been recruited leading to a wider range of anxiety levels as well as cognitive abilities.
Finally, any investigation of this type must control for medication effects. As 
protease inhibitors become more widely available, their potential effects on cognitive 
functioning will be better described. With this knowledge, investigators will be better 
able to design their research projects to take into account these effects.
The results of this investigation failed to rule out the possibility that anxiety 
may contribute to deficits in cognitive functioning in HTV seropositive patients, nor did 
it confirm this possibility. Although the stated goal of the project was to rule out a role 
for anxiety, it is important to note that regardless of the reason for these deficits, many 
patients continue to complain of subtle changes in their cognitive abilities, and these 
complaints should be taken seriously. This investigation does, however, point to 
specific improvements that can be made for future research endeavors, and highlights a 
need for further investigation, especially in the area of medication effects of the newer 
classes of anti-retroviral medication.
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Appendix A 
CDC (1992) Category A Conditions
- Asymptomatic HIV infection
- Persistent generalized lymphadenopathy
- Acute primary HTV infection with accompanying illness or history of acute HIV 
infection
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Appendix B
CDC (1992) Category B Symptoms:
Attributed to or Requiring Management Complicated by HIV
- Bacillary angiomatosis
- Candidiasis, oropharyngeal (thrush)
- Candidiasis, vulvovaginal; persistent, frequent, or poorly responsive to therapy
- Cervical dysplasia (moderate or severe)/cervical carcinoma in situ
- Constitutional symptoms, such as fever (38.5 C) or diarrhea lasting more than one 
month
- Hairy leukoplakia, oral
- Herpes zoster (shingles), involving at least two distinct episodes or more than one
dermatome
- Idiopathic thrombocytopenic purpura
- Listeriosis
- Pelvic inflammatory disease, particularly if complicated tubo-ovarian abscess
- Peripheral neuropathy
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Appendix C
Conditions Included in the 1993 ADDS 
Surveillance Case Definition (CDC, 1992)
- Candidiasis of bronchi, trachea, or lungs
- Candidiasis, esophageal
- Cervical cancer, invasive
- Coccidioidomycocis, disseminated or extrapulmonary
- Cryptococcosis, extrapulmonary
- Cryptosporidiosis, chronic intestinal (> I month's duration)
- Cytomegalovirus disease (other than liver, spleen, or nodes)
- Cytomegalovirus retinitis (with loss of vision)
- Encephalopathy, HIV - related
- Herpes simplex: chronic ulcer(s) (> 1 month’s duration); or bronchitis, Pneumonitis, or
esophagitis
- Histoplasmosis, disseminated or extrapulmonary
- Isosporiasis, chronic intestinal (> I month's duration)
- Kaposi's sarcoma
- Lymphoma, Burkitt's (or equivalent term)
- Lymphoma, immunoblastic (or equivalent term)
- Lymphoma, primary, of brain
- Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary
- Mycobacterium tuberculosis, any site (pulmonary or extrapulmonary)
- Mycobacterium, other species or unidentified species, disseminated or extrapulmonary
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- Pneumocystis carinii pneumonia
- Pneumonia, recurrent
- Progressive multifocal leukoencephalopathy
- Salmonella septicemia, recurrent
- Toxoplasmosis of brain
- Wasting syndrome due to HTV
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Appendix D 
Instructions to Examiners 
Words in all capital letters are spoken by the examiner. Please remember to obtain a 
performance appraisal after each of the dependent variables (refer to Performance 
Appraisal Sheet for instructions).
1. Wide Range Achievement Test Reading - Present the reading list to the subject and 
say: LOOK AT EACH OF THESE WORDS CAREFULLY (point). READ THE 
WORDS ACROSS THE PAGE SO I CAN HEAR YOU. WHEN YOU FINISH THE 
FIRST LINE, GO TO THE NEXT LINE AND SO ON. Allow 10 seconds for the 
subject to respond. If he/she is in the middle of a response allow him/her to continue. If 
there is no response, say: TRY THE NEXT ONE PLEASE. After the first error, the 
individual should be asked to repeat the word which was missed. If the word is said 
correctly, score as correct. No other help should be given. Do not ask the subject to 
repeat any other words unless you could not hear the subject. In that case say: I COULD 
NOT HEAR YOU CLEARLY. PLEASE SAY THE WORD AGAIN JUST AS YOU 
DID THE FIRST TIME. For this study, the subjects need only correctly read 22 words 
before missing 10 in a row. If they miss 10 in a row before correctly reading 22 they 
may not be included in the sample. Do not count off if the person has poor diction, or if 
the error can be attributed to his/her dialect. Circle the number before each item 
pronounced correctly, and draw a line through the first letter of each word pronounced 
incorrectly.
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2. CES-D - CIRCLE THE NUMBER FOR EACH STATEMENT WHICH BEST 
DESCRIBES HOW OFTEN YOU FELT THIS WAY DlJRrNG THE PAST WEEK.
3. Self-Evaluation Questionnaire (State) - A NUMBER OF STATEMENTS THAT 
PEOPLE HAVE USED TO DESCRIBE HOW THEY FEEL ARE GIVEN BELOW. 
READ THE STATEMENTS BELOW AND INDICATE HOW YOU FEEL AT THE 
MOMENT BY CIRCLING THE APPROPRIATE NUMBER.
4.Shiplev Institue of Living Scale - Part I IN THE TEST BELOW, THE FIRST WORD 
IN EACH LINE IS PRINTED IN CAPITAL LETTERS. OPPOSITE IT ARE FOUR 
OTHER WORDS. CIRCLE THE ONE WORD WHICH MEANS THE SAME THING. 
OR NEARLY THE SAME THING AS THE FIRST WORD. IF YOU DONT KNOW, 
GUESS. BE SURE TO CIRCLE TEH ONE WORD IN EACH LINE THAT MEANS 
THE SAME THING AS THE FIRST WORD. The subject is given ten minutes or until 
he/she indicates that he/she is finished to complete Part I. Part H COMPLETE THE 
FOLLOWING BY FILLING DM EITHER A NUMBER OF A LETTER FOR EACH 
DASH. DO THE ITEMS IN ORDER, BUT DONT SPEND TOO MUCH TIME ON 
ANY ONE ITEM. Again the subject is given ten minutes or until he/she indicates that 
he/she is finished.
5. Rev Auditory Verbal Learning Test - 1 AM GOING TO READ A LIST OF WORDS. 
LISTEN CAREFULLY, FOR WHEN I STOP YOU ARE TO REPEAT BACK AS
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MANY WORDS AS YOU CAN REMEMBER. IT DOESN'T MATTER WHAT 
ORDER YOU REPEAT THEM. JUST TRY TO REMEMBER AS MANY AS YOU 
CAN. Read List A 1 aloud, with a one second interval between each word. Use numbers 
to keep track of the participant's pattern of recall. No feedback should be given. When 
the participant indicates that he/she can recall no more words, the examiner rereads the 
list after giving the following set of instructions. NOW I'M GOING TO READ THE 
SAME WORDS AGAIN, AND ONCE AGAIN WHEN I STOP I WANT YOU TO 
TELL ME AS MANY WORDS AS YOU CAN REMEMBER, INCLUDING THE 
WORDS YOU SAID THE FIRST TIME. IT DOESN'T MATTER IN WHAT ORDER 
YOU SAY THEM. JUST SAY AS MANY WORDS AS YOU CAN REMEMBER, 
WHETHER OR NOT YOU SAID THEM BEFORE. The Iixt is reread for Trials A3 
through A5 using Trial A2 instructions each time. After trial A5, the examiner reads 
List B with instructions as on the first A trial: NOW I'M GOING TO READ A 
SECOND LIST OF WORDS. THIS TIME, YOU ARE TO SAY BACK AS MANY 
WORDS OF THIS SECOND LIST AS YOU CAN REMEMBER. THE ORDER IN 
WHICH YOU SAY THESE WORDS DOES NOT MATTER. JUST TRY TO 
REMEMBER AS MANY AS YOU CAN. Immediately after recall B l, as for recall of 
the first list (Trial A6) without further presentation o f those words: NOW TELL ME AS 
MANY WORDS FROM THE FIRST LIST AS YOU CAN REMEMBER. After a 
twentyminute delay period filed with other activity, as the patient to recall the words 
from list A (TrialA7): NOW TELL ME AS MANY WORDS FROM THE FIRST LIST 
AS YOU CAN REMEMBER.
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6. Trail Making Test (Part A) - Place the Part A sample sheet on the table directly in 
front of the subject six inches from the edge of the table. Give subject the pencil and 
say: ON THIS PAGE (point) ARE SOME NUMBERS. BEGIN AT THE NUMBER 1 
(point to 1) AND DRAW A LINE FROM 1 TO 2 (point to 2), 2 TO 3 (point to 3), 3 TO 
4 (point to 4), AND SO ON, IN ORDER UNTIL YOU REACH THE END (point to the 
circle marked "end"). DRAW THE LINES AS FAST AS YOU CAN. READY! BEGIN! 
If the subject completes the sample items correctly, and in manner which showa that 
he/she knows what to do, say: GOOD! LETS TRY THE NEXT ONE. Give Part A of 
the test following the instructions below.
If the subject makes a mistake on Sample A, point out the error and explain it. 
The following explanations of mistakes serve as illustrations.
A. YOU STARTED WITH THE WRONG CIRCLE. THIS IS WHERE YOU 
START (point to the number 1).
B. YOU SKIPPED THIS CIRCLE (point to the circle omitted). YOU SHOULD 
GO FROM NUMBER 1 (point), TO 2 (point), 2 TO 3 (point), AND SO ON, UNTIL 
YOU REACH THE CIRCLE MARKED END (point). If it is clear that the subject 
intended to touch the circle but missed it, do not count it as an omission, but caution the 
subject to touch the circles.
If the subject still cannot complete the sample, take his/her hand and guide the 
pencil (eraser end down) through the trail. Then say: NOW YOU TRY IT. Return the 
pencil to the subject and say: REMEMBER, BEGIN AT NUMBER 1 (point) AND 
DRAW A LINE FROM 1 TO 2 (point to 2), 2 TO 3 (point to 3), 3 TO 4 (point to 4),
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AND SO ON IN ORDER, UNTIL YOU REACH TEH CIRCLE MARKED END 
(point). DO NOT SKIP AROUND, BUT GO FROM ONE NUMBER TO THE NEXT 
IN THE PROPER ORDER. REMEMBER TO WORK AS FAST AS YOU CAN. 
READY! BEGIN! If the subject succeds this time, go on to Part A. If not, repeat the 
procedure until he/she does or until it is evident that he/she cannot.
Test Instructions. ON THIS PAGE ARE NUMBERS FROM I TO 25. DO THIS 
THE SAME WAY. BEGIN AT NUMBER 1 (point) AND DRAW A LINE FROM 1 TO 
2 (point to 2), 2 TO 3 (point to 3), 3 TO 4 (point to 4) AND SO ON, IN ORDER, 
UNTIL YOU REACH THE END (point to 25). REMEMBER, WORK AS FAST AS 
YOU CAN. READY! BEGIN! Start timing and do not stop. Watch the subject closely 
and correct any errors immediately by having the subject proceed from the point the 
mistake occurred. Record the time to complete the test.
7. Trail Making Test (Part B) - NOW WE'LL TRY ANOTHER ONE. Place Sample B 
in front of the participant and say: ON THIS PAGE ARE SOME NUBERS AND 
LETTERS. BEGIN AT NUMBER 1 (point) AND DRAW A LINE FROM 1 TO A 
(point to A), A TO 2 (point to 2), 2 TO B (point to B), B TO 3 (point to 3), 3 TO C 
(point to C), AND SO ON, IN ORDER UNTIL YOU REACH THE END (point to the 
circle marked "end"). REMEMBER, FIRST YOU HAVE A NUMBER (point to 1), 
THEN A LETTER (point to A), THEN A NUMBER (point to 2), THEN A LETTER 
(point to B), AND SO ON. DRAW THE LINES AS FAST AS YOU CAN. READY!
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BEGIN! If the subject completes the sample correctly, say: GOOD. LETS TRY THE 
NEXT ONE. Administer the test with the instructions below.
If the subject makes a mistake, point it out and explain it similarly to the 
explanations for mistakes for part A. If the subject still cannot complete the sample, 
guide his/her hand as before. Then repeat the instructions and encourage the subject to 
try again. If the subject succeeds, procede to the test, if not, continue to explain it until 
he/she does succeed, or until it becomes obvious that he/she cannot.
Test Instructions ON THIS PAGE ARE NUMBERS AND LETTERS. DO THIS 
THE SAME WAY. BEGIN AT NUMBER 1 (point), AND DRAW A LINE FROM 1 
TO A (point to A), A TO 2 (point to 2), 2 TO B (point to B), B TO 3 (point to 3), 3 TO 
C (point to C), AND SO ON, IN ORDER, UNTIL YOU REACH THE END (point to 
the circle marked "end"). REMEMBER, FIRST YOU HAVE A NUMBER (point to 1), 
THEN A LETTER (point to A), THEN A NUMBER (point to 2), THEN A LETTER 
(point to B), AND SO ON. DON NOT SKIP AROUND, BUT GO FROM ONE 
CIRCLE TO THE NEXT IN PROPER ORDER. DRAW THE LINES AS FAST AS 
YOU CAN. READY! BEGIN! Start timing and do not stop. If the subject makes an 
error, call it to the subject's attention immediately and have him/her proceed from the 
point the mistake occurred. Record the time to complete the test.
8. Block Design - Place four blocks in view of the subject and say: YOU SEE THESE 
BLOCKS? THEY ARE ALL ALIKE. ON SOME SIDES THEY ARE ALL RED; ON 
SOME, ALL WHITE; AND ON SOME, HALF RED AND HALF WHITE. Hold up one
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block and turn it to show each side. Then say: I'M GOING TO PUT THEM 
TOGETHER TO MAKE A DESIGN, WATCH ME. Arrange the four blocks slowly into 
the design shown on card 1, without exposing the card to the subject. Then, leaving the 
model intact, give four other blocks to the subject and say: NOW MAKE ONE JUST 
LIKE THIS. Start timing. Allow 60 seconds. If the subject successfully completes the 
design within the time limit, proceed to Design 2. If the subject fails, say: WATCH ME 
AGAIN. Demonstrate again using the subject’s blocks. Then scramble the dubject’s 
blocks and say: NOW YOU TRY IT AGAIN AND BE SURE TO MAKE IT JUST 
LIKE MINE. Start timing again and allow 60 seconds. Regardless of performance, 
proceed to design 2. If the subject attempts to match the examiner’s design exactly (all 
sides) tell him/her that only the top needs to be duplicated.
Design 2 Scramble the subject’s blocks. Remove the blocks that served as the model for 
design 1 and put in their place the card marked (2). Say: THIS TIME WE ARE GOING 
TO PUT THE BLOCKS TOGETHER TO MAKE THEM LOOK LIKE THIS 
PICTURE. Point to the card, then say: WATCH ME FIRST. Construct the design 
slowly, then say: YOU SEE THE TOPS OF THESE BLOCKS LOOK THE SAME AS 
THIS PICTURE. Scramble the blocks used in the demonstration and say: NOW LOOK 
AT THE PICTURE AND MAKE ONE JUST LIKE IT WITH THESE BLOCKS. GO 
AHEAD. Allow 60 seconds. If the subject successfully completes the design, proceed to 
Design 3. If the subject fails, scramble the blocks and say: WATCH ME AGAIN. Make 
the design again, then scramble it and say: NOW TRY IT AGAIN. Allow 60 seconds. 
Regardless of performance, continue to Design 3.
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Design 3-9 Scramble the blocks and put out the card marked (3). Say: NOW MAKE 
ONE LIKE THIS. TRY TO WORK AS QUICKLY AS YOU CAN. TELL ME WHEN 
YOU HAVE FINISHED. Start timing and allow 60 seconds. When the subject has 
completed the design or time is up, scramble the block and continue with the next 
design using the same instructions, or a shortened version once the subject understands 
the task. For Design 6 say: NOW MAKE ONE LIKE THIS USING NINE BLOCKS. BE 
SURE TO TELL ME WHEN YOU HAVE FINISHED. For Design 9, do not permit the 
subject to rotate the card. Continue the test until the subject has failed 3 consecutive 
trials. A two-trial design is considered failed only if both trials are failed.
9. Grooved Pegboard Test - THIS IS A PEGBOARD, AND THESE ARE PEGS. Point 
to each, then pick up one of the pegs. ALL OF THE PEGS ARE THE SAME. THEY 
HAVE A GROOVE. THAT IS, A ROUND SIDE, AND A SQUARE SIDE, AND SO 
DO THE HOLES IN THE BOARD. WHAT YOU MUST DO IS MATCH THE 
GROOVE OF THE PEG WITH THE GROOVE OF THE BOARD AND PUT THSES 
PEGS INTO THE HOLES LIKE THIS. Demonstrate by filling the top row, then take 
them out again. WHEN I SAY GO, BEGIN HERE AND PUT THE PEGS INTO THE 
BOARD AS FAST AS YOU CAN USING ONLY YOUR (DOMINANT) HAND. FILL 
THE TOP ROW COMPLETELY FROM THIS SIDE TO THIS SIDE (demonstrate left 
to right when using right hand, and right to left when using left hand). DO NOT SKIP 
ANY. FILL EACH ROW THE SAME WAY YOU FILLED THE TOP ROW. ANY
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QUESTIONS? READY, AS FAST AS YOU CAN GO. Begin timing and stop when 
last peg is in its hole.
10. Digit Span Forward - I’M GOING TO SAY SOME NUMBERS. LISTEN 
CAREFULLY, AND WHEN I AM THROUGH SAY THEM RIGHT AFTER ME. The 
digits should be given at the rate of one per second. Let the pitch of voice drop on the 
last digit of each trial. Administer both trials of each item, even if the subject passes 
trial 1. Discontinue after failure on both trials of any item. Give 2 points if the subject 
passes both trials, 1 point if the subject passes only 1, and 0 points if the subject fails 
both trials.
11. Remember to give the RAVLT delay.
12. F-A-S Test - Ignore the instructions at the top of the page. I WANT YOU TO 
NAME AS MANY WORDS AS YOU CAN THAT BEGIN WITHT THE LETTER OF 
THE ALPHABET THAT I WILL GIVE YOU. THERE ARE TWO RULES. FIRST, 
YOU CANNOT USE DIFFERENT FORMS OF THE SAME WORD. FOR EXAMPLE, 
IF I GAVE YOU (G), YOU COULD SAY GO, BUT YOU COULD NOT THEN SAY 
GOES OR GONE. SECOND, YOU CANNOT USE PROPER NAMES, FOR 
EXAMPLE THE NAME OF A PERSON ORE A CITY. NOW HOW MANY WORDS 
CAN YOU THINK OF THAT BEGIN WITHT THE LETTER .Allow 60
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seconds, and write down all of the words that the subject says in the proper column 
depending on the time that he/she says the word. Do not adminster animals.
13. Paced Auditory Serial Addition Test - 1 AM GOING TO ASK TO ADD 
TOGETHER PAIRS OF SINGLE-DIGIT NUMBERS. YOU WILL HEAR A TAPE- 
RECORDED LIST OF NUMBERS READ ONE AFTER ANOTHER. I WILL ASK 
YOU TO ADD THE NUMBERS IN PAIRS AND GIVE YOU ANSWERS OUT 
LOUD. ALTHOUGH THIS IS REALLY A CONCENTRATION TASK, AND NOT A 
TEST TO SEE HOW WELL YOU CAN ADD, IT MIGHT TO DO A LITLLE ADDING 
BEFORE I EXPLAIN THE TASK IN MORE DETAIL. PLEASE ADD THE 
FOLLOWING PAIRS OF NUMBERS TOGETHER AS FAST AS YOU CAN, AND 
GIVE YOUR ANSWERS OUT LOUD: 3,8 (11); 4,9 (13); 7,8(15); 8,6(14); 8,9(17);
5,7( 12); 6,5( 11); 6,9( 15); 4,7(11); 7,6( 13). GOOD. If subject cannot add these numbers, 
do not administer the test. THE TASK THAT I WANT YOU TO DO INVOLVES 
ADDING TOGETHER PAIRS OF NUMBERS JUST AS YOU HAVE DONE,
EXCEPT THE NUMBERS WILL BE READ AS A LIST ONE AFTER THE OTHER. 
LET ME GIVE YOU AN EXAMPLE WITH A SHORT, EASY LIST. SUPPOSE I 
GAVE YOU THE FOLLOWING: 1,2,3,4. HERE’S WHAT YOU WOULD DO. AFTER 
HEARING THE FIRST TWO NUMBERS ON THE LIST WHICH WERE 1,2, YOU 
WOULD ADD THESE TOGETHER AND GIVE YOUR ANSWER, 3, 1 + 2 =3. THE 
NEXT NUMBER ON THE LIST IS 3, SO WHEN YOU HEARD IT, YOU WOULD 
ADD THIS NUMBER TO THE NUMBER RIGHT BEFORE IT ON THE LIST
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WHICH WAS 2, AND YOU WOULD GIVE YOUR ANSWER 5,2 + 3 = 5. ARE YOU 
FOLLOWING SO FAR? THE LAST NUMBER YOU HEARD WAS 4 (REMEMBER 
THE LIST WAS 1,2,3,4), SO YOU WOULD ADD 4 TO THE NUMBER RIGHT 
BEFORE IT WHICH WAS 3, AND GIVE YOUR ANSWER 7, 3 + 4 = 7. THE 
IMPORTANT THING TO REMEMBER IS THAT YOU MUST ADD EACH 
NUMBER ON THE LIST TO THE NUMBER BEFORE IT ON THE LIST, AND NOT 
TO THE ANSWER YOU HAVE JUST GIVEN. YOU CAN FORGET YOUR 
ANSWERS AS SOON AS YOU HAVE SAID THEM. ALL YOU HAVE TO 
REMEMBER IS THE LAST DIGIT THAT YOU HEARD AND ADD IT TO THE 
NEXT DIGIT THAT YOU HEAR. O.K.? LET’S TRY A SHORT LIST AGAIN, ONLY 
THIS TIME YOU SAY THE ANSWERS. READY? 1,2 (3); 3 (5); 4 (7); NOW LET’S 
TRY ANOTHER, LONGER PRACTICE LIST OF NUMBERS, THIS TIME THE 
NUMBERS ON THE LIST WILL NOT BE IN ANY PARTICULAR ORDER.
READY? 4,6 (10); 1 (7); 8 (9); 8 (16); 4 (12); 3 (7); 8 (11); 2 (10); 7 (9). GOOD.
If the subject has difficult understanding the oral directions, then provide a 
written demonstration. THAT SOUNDS COMPLICATED, LET ME SHOW YOU 
WHAT I MEAN. Write down a list of numbers (5,3,7,4,2) YOU SEE, YOU ADD THE 
5 AND THE 3 TOGETHER AND SAY 8. THEN YOU HAVE TO FORGET THE 8 
AND REMEMBER THE 3. WHEN THE 7 COMES ALONG, YOU ADD IT TO THE 
3, AND SAY 10. NOW YOU HAVE TO REMEMBER THE 7. ALRIGHT. WHAT DO 
YOU SAY AFTER 4? Continue until the subject understands what to do. Say:
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IT’S VERY EASY WHEN ALL THE NUMBERS ARE WRITTEN DOWN FOR YOU. 
TRY IT WITH ME SAYING SOME NUMBERS TO YOU. Say some more.
REMEMBER, I SAID THE NUMBERS WOULD BE TAPE-RECORDED?
THE TASK IS NOT EASY, AND NO ONE IS EXPECTED TO GET ALL OF THE 
ANSWERS RIGHT. THE HARD PART IS KEEPING UP WITH THE SPEED OF THE 
RECORDING. HOWEVER, IF YOU CAN’T ANSWER IN TIME, DON’T WORRY. 
JUST WAIT UNTIL YOU HEAR TWO MORE NUMBERS; ADD THEM 
TOGETHER, AND GO ON FROM THERE. O.K.? I’LL PLAY A PRACTICE LIST OF 
NUMBERS, AND GET YOU TO GIVE ME THE ANSWERS. Play practice list.
YOU SEE WHAT I MEAN ABOUT THE TASK MEASURING HOW WELL 
YOU CAN CONCENTRATE. IT DOESN’T HAVE ANYTHING TO DO WITH HOW 
SMART YOU ARE. NOW WE’LL TRY THE FIRST REAL TRIAL. THIS TRIAL IS 
JUST THE SAME AS THE PRACTICE TRIAL YOU’VE JUST DONE, EXCEPT 
THAT IT IS SIX TIMES AS LONG, SO IT GOES ON FOR ABOUT THREE 
MINUTES. DON’T WORRY IF YOU MAKE ADDING MISTAKES, OR MISS SOME 
ANSWERS. THIS IS A DIFFICULT TASK. I WANT TO SEE NOT ONLY HOW 
LONG YOU CAN KEEP GOING WITHOUT STOPPING, BUT ALSO HOW 
QUICKLY YOU CAN PICK UP AGAIN IF YOU DO STOP. NO ONE IS EXPECTED 
TO GET ALL THE ANSWERS. AFTER THIS TRIAL WE WILL TAKE A BREAK 
AND THEN DO ANOTHER TRIAL AT A FASTER SPEED. Follow along with 
subject writing the subject’s responses in the blanks provided.
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